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Abstract: The first synthesis of carbasugars, compounds in which the ring oxygen of a 
monosaccharide had been replaced by a methylene moiety, was described in 1966 by 
Prof. G.E. McCasland’s group. Seven years later, the first true natural carbasugar (5a-
carba-R-D-galactopyranose) was isolated from a fermentation broth of Streptomyces sp. 
MA-4145.  In the following decades, the chemistry and biology of carbasugars have 
been extensively studied. Most of these compounds show interesting biological 
properties, especially enzymatic inhibitory activities and, in consequence, an important 
number of analogues have also been prepared in the search for improved biological 
activities. The aim of this review is to give coverage on the progress made in two 
important aspects of these compounds: the elucidation of their biosynthesis and the 
consideration of their biological properties, including the extensively studied 
carbapyranoses as well as the much less studied carbafuranoses.  
 
1. Introduction. 
 
In addition to their well-known role as chemical units for a) release of energy such as 
sucrose or glucose, b) energy storage such as starch or c) as responsible for structure 
and strength such as cellulose, carbohydrates are key elements in a variety of biological 
processes. In fact, the concept of glycomic has been defined as “the functional study of 
carbohydrates in living organism”.[1 ] Carbohydrates are key elements in a variety of 
processes such as signaling, cell-cell communication, and molecular and cellular 
targeting. Many biological processes involve carbohydrates and, in consequence, the 
biological implications of carbohydrates are strongly related with many diseases. In this 
context, it should be pointed out that the synthetic-carbohydrate vaccines show potential 
advantages over those based on carbohydrates from natural sources. Thus, medicinal 
chemistry techniques can potentially be used to derivatize and modify synthetic 
carbohydrates to make vaccines that are more immunogenic than those based on natural 
carbohydrates. For selected, general and recent reviews on these aspects of carbohydrate 
chemistry, see: (a) general teatrises: references [2-5]; (b) synthetic aspects: references 
[6-7]; (c) carbohydrates in biological and medicinal chemistry: references [8-11]; (d) 
glycobiology [12]; (d) signaling, cell-cell communication, and molecular and cellular 
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targeting: references [13-18]; (e) therapeutic potential of glycoconjugates: references 
[19-20]; (f) carbohydrate-based vaccines: references [21-25].    
 
On the other hand, novel carbohydrate structures whose biological functions were not 
always obvious have been discovered. For instance, intriguing compounds such as sialyl 
Lewis X (sLex) [26-28] or glycosylphosphatidylinositols (GPIs) are now known to play 
a pivotal role in numerous biological functions.[29-34] Moreover, carbohydrates 
constitute a very useful source of enantiomerically pure starting materials. They have 
been used for the synthesis of a wide range of compounds and have been found to be 
useful chiral auxiliaries which allowed the introduction of a range of functionalities in a 
highly enantioselective manner.[35-36] 
 
On this basis, the search for new carbohydrate derivatives with analogous or even 
improved biological properties compared to those of the parent structures (the 
carbohydrate mimetics) [37-40] appears to be an attractive matter of research. The 
carbasugars (initially, the term pseudosugars was coined for this family of compounds, 
although they are currently known as carbasugars [41]), compounds in which the ring 
oxygen of a monosaccharide had been replaced by a methylene group (Figure 1), fall 
within this category [42-46]. The structural resemblance of carbasugars to the parent 
sugars may facilitate their recognition by enzymes or other biological systems in place 
of the related true sugars. On the other hand, these compounds could be more stable 
toward endogenous degradative enzymes. 
 
The aim of this review is to give coverage on the progress made in the biosynthesis and 
biological activity of carbasugars until March 2016, including both carbapyranoses and 
carbafuranoses. 
 
  
Figure 1. Monosaccharides and Carbamonosaccharides. 
 
2. Natural Occurrence of Carbasugars. 
 
2.1. Natural Carbafuranoses. 
 
Carbafuranoses are scarcely encountered in Nature as free compound. Nevertheless, 
they are subunits of products isolated from natural sources, in particular 
carbanucleosides [47-48]. To the best of our knowledge, only two five-membered 
cyclitols derivatives have been isolated from natural sources (Figure 2): Caryose 1 [49-
51], isolated from the lipopolysaccharide fraction of Pseudomonas caryophylli (a plant 
pathogenic bacteria), and calditol 2, isolated from the thermoacidophilic 
archaebacterium Sulfolobus acidocaldarius, a thermoacidophilic archaeon belonging to 
Sulfolobus species. These species was found to grow optimally between 75-80º C, with 
pH optimum in the range of  2-3  [52-55]. The original proposed structure for calditol, 
an open-chain branched nonitol 3, was soon questioned by various research groups. To 
unambiguously clarify this point, four isomeric cyclopentane-based structures were 
synthesized by Sinaÿ et al. Among them, compound 2 was found to be fully identical to 
the natural product present in several Sulfolobus species [56-57]. 
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2.2. Natural Carbapyranoses 
 
Carbapyranoses have been encountered in Nature rarely being carba-α-D-
galactopyranose (4, Figure 3) the only “genuine” carbasugar isolated from natural 
sources (Streptomyces sp) [58]. 
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Figure 2. Structure of Caryose 1, proposed structure of Calditol 3 and structure of 
Calditol 2 
 
However they are abundant as subunits of other natural products. On the other hand a 
large number of highly oxygenated cyclohexane and cyclohexene derivatives, closely 
related to carbasugars, have been isolated from Nature. Among them, epoxides [59-60] 
such as cyclophellitol (isolated from Phellinus sp)[61-65] (5, Figure 3), cyclohexene 
derivatives such as MK7607 (isolated from Curvularia eragestrides) [66], (6, Figure 3), 
streptol (isolated from Streptomyces sp) [67-68], (7, Figure 3), pericosines A-D 
(isolated from Periconia byssoides) (8-13, Figure 4) [69-70], carbonyl compounds such 
as the gabosine family (isolated from various Streptomyces strains) [71-73] (Figure 5, 
15-28), COTC (isolated from Streptomyces griseosporeus)[74] (Figure 5, 29) and 
valienona (isolated from Strptomyces lincolnensis) [68] (Figure 5, 30). 
 
  
Figure 3. Some natural carbapyranoses: carba-α-D-galactopyranose, cyclophellitol, 
MK7607 and stretptol. 
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Figure 4. The pericosines. 
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Figure 5. Gabosines, COTC and valienone. The absolute configuration of gabosines H 
(23) and J (25) remains, to the best of our knowledge, unknown. 
 
Aminocarbasugars, such as valienamine (31) and validamine (32) (natural sources of 
validamine, include microbial degradation procedures [75-79], chemical degradation of 
validoxylamine-see below-) using NBS [80-81] and several biotechnological processes 
[82-84], hydroxyvalidamine [85] (33), and valiolamine [86-87] (34) (Figure 6), have 
been mainly found as subunits of more complex molecules (Vide infra). These 
derivatives are secondary metabolites exclusively produced by microorganisms. They 
have been detected only as minor components in the fermentation broth of Streptomyces 
hygroscopicus subsp. Limoneus [87]. Aminocarbasugars are mainly found in 
validamycins, acarbose, and related carbaoligosaccharides. 
 
  
Figure 6. Aminocarbasugars valienamine, validamine, hydroxyvalidamine and 
valiolamine. 
 
Validamycins (Figure 7) are a family of antibiotics discovered during the screening for 
new antibiotics from the fermentation culture of Streptomyces hygroscopicus.[88-91] 
The main component of the complex is Validamycin A (35), a pseudotrisaccharide 
consisting of a core moiety, validoxylamine A (43), and D-glucopyranose. The core 
consists of two aminocyclitols, valienamine (31), and validamine (32), which are 
connected through a single nitrogen atom. Validamycin B (36) differs from validamycin 
A in the second aminocyclitol unit which, in validamycin B (36), is hydroxyvalidamine 
(33). The minor components of the validamycins complex, validamycins C-F (37-40) 
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and validamycin H (42), contain validoxylamine A (43), as the core unit, but they differ 
in at least one of the following features: (a) the position of the glucosidic linkage, (b) 
the number of D-glucopyranose residues, or (c) the anomeric configuration of the D-
glucopyranose unit [92-95]. Validamycin G (41) contains validoxylamine G (45) as its 
core unit. 
 
  
Figure 7. The Validamycins family. 
 
Acarbose (Figure 8, 46) [96-97] is one of the most clinically important compounds 
containing carbasugar units, since it is currently used for the treatment of type II insulin-
independent diabetes. This disease is a metabolic disorder that is characterized by 
hyperglycemia in the context of insulin resistance and relative lack of insulin [98-99]. In 
addition to acarbose, marketed by Bayer, there are two drugs, structurally related with 
acarbose, which belong to this class of -glucosidase inhibitors: miglitol 47 –Sanofi- 
and voglibose 48 –Takeda-  (Figure 8). Acarbose is a starch blocker, and inhibits α-
amylase, an intestinal enzyme that releases glucose from larger carbohydrates [100-101]. 
Acarbose is a carbatrisaccharide which was found in a screening of strains of various 
Actinomycete genera and its structure was determined by degradation reactions, 
derivatization, and spectroscopic analysis. It is composed of valienamine (31), a 
deoxyhexose (4-amino-4,6-dideoxyglucose), and maltose. The carbadisaccharic core of 
acarbose, known as acarviosine (49), is postulated to be essential for its biological 
activity. The core unit, 49, is also linked to a variable number of glucose residues, 
resulting in several other components of the complex mixture of acarbose. The 
formation of these components is highly dependent on the composition of the carbon 
source available in the culture medium. Media containing glucose and maltose will 
result in a specifically high yield of acarbose and the lower components, while media 
with high concentrations of starch will yield longer oligosaccharide species. The 
transglycosylation involved in this process was proposed to be catalyzed by an 
extracellular enzyme, acarviosyl transferase, found in the culture of the acarbose 
producer [102]. Acarbose has been the subject of interest and excellent reviews have 
been published, covering various specific aspects on the biochemistry and molecular 
biology of this compound [103-114]. 
 
The amylostatins, with general structure 50 (Figure 9), are related to acarbose analogues 
due to they contain the acarviosine core 49. Amylostatins were isolated in the culture 
filtrate of Streptomyces diastaticus subsp. Amilostaticus [115-116]. 
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Figure 8. Structures of acarbose, acarviosine and marketed products 47 and 48. 
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Figure 9. The amylostatins. 
 
Adiposins (51, Figure 10) were isolated from Streptomyces calvus [117-124]. 
Structurally, adiposins are related to acarbose (46) and amylostatins (50). They are 
formed by an aminocarbasugar (valienamine, 31)) and a deoxy sugar (4-amino-4- 
deoxyglucose). 
 
  
Figure 10. The adiposins. 
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Oligostatins (52, Figure 11) were obtained from culture broths of Streptomyces 
myxogenes [125-129]. They are carbaoligosaccharide antibiotics consisting of penta-, 
hexa-, and heptasaccharides containing hydroxyvalidamine rather than valienamine. 
 
  
Figure 11. The oligostatins. 
 
Trestatins (53, Figure 12) were isolated from fermentation cultures of Streptomyces 
dimorphogenes [130-131]. These carbaoligosaccharides contain one to three dehydro-
oligobioamine units and terminate with one residue of α-D-glucopyranose linked 1,1- to 
the preceding glucose unit. Therefore, unlike the oligostatins 52 and the amylostatins 50, 
the trestatins are nonreducing carbohydrates 
 
  
Figure 12. The trestatins. 
 
Trehalase inhibitor salbostatin (54, Figure 13) is a metabolite of Streptomyces albus 
species [132-134]. This basic nonreducing carbadisaccharide consisting of valienamine 
linked to 2-amino-1,5-anhydro-2-deoxyglucitol.  
 
In 1995, the pyralomicins (55-58, Figure 14) were isolated from the strain of 
Actinomadura spiralis (which was later renamed Microtetraspora spiralis)[135-136]. 
Their chemical structures consist of benzopyranopyrrole chromophores containing a 
nitrogen atom which is also shared with 1-epi-valienamine.[137]. Pyralomicins are, thus 
far, the only examples of natural products having an aminocarbasugar unit, acting as the 
glycone, attached to a polyketide-derived core structure [138-140]. 
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Figure 13. Structure of Salbostatin. 
 
  
Figure 14. The pyralomicins. 
 
3. Biosynthesis of carbasugars. 
 
3.1. Carbafuranoses. 
 
The biosynthesis of carbapentofuranoses has only been considered in the literature, to 
the best of our knowledge, in the context of the more biologically relevant carbocyclic 
nucleosides and in the case of the cyclitol calditol 2. 
 
3.1.1. Carbocyclic nucleosides. 
 
Biosynthetic studies on aristeromycin (59) and neplanocin A (60) (Figure 15)[141-144] 
had established that the carbocyclic ribose ring was biosynthesize from D-glucose via 
the enone 61, the first-formed carbocyclic intermediate. After reduction of the double 
bond in 61, the reduction of ketone function of the resulting product 62 in an anti 
fashion and phosphorylation afford the carbocyclic analogue of 5-phosphoribosyl- 1-
pyrophosphate 63 (Scheme 1). A detailed description of this sequence was described in 
Reference 42, p. 1923-1924.  
 
  
Figure 15. Structures of Aristeromycin 59 and neplanocin 60.  
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Scheme 1. Proposed biosynthesis of carbaphosphorybosyl-1-phosphate from glucose. 
 
3.1.2. Biosynthesis of Calditol. 
 
Calditol 2 constitutes the cyclitol moiety of lipids such as 64 (Figure 16) and related 
compounds which are present in microorganisms belonging to the Archaea domain. As 
shows in Figure 16, the cyclitol fragment is linked to the rest of the molecule by 
ethereal bonding [145].  
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Figure 16. Structure of the lipids isolated from Archae. 
 
From experiments using C-3 and C-4 deuterated glucose and galactose, a biosynthetic 
‘inositol like’ pathway for the cyclopentanoid part of calditol has been proposed [146-
149]. The sequence involves the formation of a 1,5 carbon bond mediated by a 
“cyclase” enzyme, followed by a stereospecific reduction at C-4 (Scheme 1). Regarding 
Caryose 1 no biogenetic proposal has been found in the literature.  
 
3.2. Carbapyranoses. 
 
3.2.1. Sedo-heptulose 7-phosphate. 
 
Sedo-heptulose 7-phosphate (75), is a key intermediate in the biosynthetic pathway of 
valienamine and gabosines A, B, C and H. This compound derives from the pentose 
phosphate pathway [150-151]. The pentose phosphate pathway is the source of NADPH 
68 used in reductive biosynthetic reactions and consists in two phases: the oxidative 
generation of NADPH (Scheme 3) and the nonoxidative interconversion of sugars 
(Scheme 4). 
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Scheme 1. Proposed biosynthesis of Calditol 2. 
 
In the oxidative phase, NADPH is generated from glucose 6-phosphate 65 and starts 
with the dehydrogenation 65 at C1 to give 6-phosphoglucono-δ-lactone 67 in a reaction 
catalyzed by glucose 6-phosphate dehydrogenase and mediated by NADP+ (66). The 
next step is the hydrolysis of 6-phosphoglucono-δ-lactone 67 by a specific lactonase (6-
phosphonogluconolactonase) to give 6-phosphogluconate 69. This six-carbon sugar is 
then oxidatively decarboxylated by 6-phosphogluconate dehydrogenase to yield 
ribulose 5-phosphate 70. In the non-oxidative phase, ribulose-5-phosphate 70 is 
transformed into xylulose-5-phosphate 71 and ribose-5-phosphate 72 via epimerization 
at C-3 and isomerization (through an enolate ion) respectively. Finally, a sequence of 
retroaldol-aldol reaction mediated by thyamine pyrophosphate 73 results in the 
formation of sedo-heptulose-5-phosphate 75 and glyceraldehyde-3-phosphate 74.  
 
3.2.2. Biosynthesis of gabosines. 
 
The cyclization process of sedo-heptulose 7-phosphate (75) to a six membered 
carbocyclic intermediate, 2-epi-5-epi-valiolone 77 [152-155] is catalyzed by a 
sedoheptulose 7-phosphate cyclase (Scheme 5). These enzymes are phylogenetically 
related to the dehydroquinate synthases (DHQS) and use Co2+ as preferred cofactor. 
Dehydroquinate synthase (DHQS) is able to perform several consecutive chemical 
reactions in one active site. There has been considerable debate as to whether DHQS is 
actively involved in all these steps, or whether several steps occur spontaneously, 
making DHQS a spectator in its own mechanism. DHQS performs the second step in 
the shikimate pathway, the transformation of 78 (3-deoxy-D-arabino-heptalusonate-7-
phosphate) into 79 (3-dehydroquinate), which is required for the synthesis of aromatic 
compounds in bacteria, microbial eukaryotes and plants (Scheme 5).[156-157]. 
 
The reaction is assumed to be initiated by transient dehydrogenation of C-5 to a ketone 
76, which sets the stage for the elimination of phosphate, followed by reduction of the 
C-5 ketone and ring-opening to produce the corresponding enolate. The latter then 
undergoes intramolecular aldol condensation to give 2-epi-5-epi-valiolone 77. This 
compound is epimerized at C2 (compound 80) and dehydrated via a syn elimination to 
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yield valienone 30 (Scheme 6). However, how exactly these final processes take place 
under the enzymatic point of view remain still obscure. 
 
The transformation of 2-epi-5-epi-valionone 77 into gabosines requires a considerable 
number of steps such as dehydration, oxidation, reduction and epimerisation as depicted 
in Scheme 7 for the transformation of 2-epi-5-epi-valiolone 77 into gabosines A, B, C 
and N through the reduction product 81 (Scheme 7) [158]. It seems possible that the 
reduction at C-7 and the oxidation at C-1 (gabosines numeration) follow a similar 
mechanism, as described for the formation of 6-deoxy-4-keto sugars [159-160]. It can 
expect a considerably high number of specific involved enzymes working in a manner 
that is really not understood. 
 
In this context a new hypothesis for the biosynthesis of gabosines from 77 has recently 
been proposed on the basis of an unexpected experimental observation [161]. When 
compound 82 (Scheme 8) was submitted to a simultaneous oxidation-elimination 
protocol by reaction with m-CPBA, a separable mixture of the expected -
hydroxymethyl enone 83 (10%) and -hydroxymethyl enone 84 (68%)  was obtained. 
The formation of 84 may be explained on the basis of a keto-enol equilibrium process 
followed by sulphide elimination. Considering that a similar keto-enol process had been 
observed [162] in a previous synthesis of gabosines N and O, a biosynthetic proposal 
starting from 2-epi-5-epi-valiolone 77 and involving keto-enol equilibrium cascade 
reactions has been formulated (Scheme 9). This kind of isomerizations has been 
observed in different biogenetic routes such as the transformation of ribulose-5-
phosphate 70 into xilulose-5-phosphate 71 and ribose-5-phosphate 72 (see Scheme 4). 
 
3.2.3. Biosynthesis of Validamycins. 
 
Valienone 30 and they reduction product validone 87 are the more proximate precursor 
of validoxylamine A 43, the aglycon moiety of validamycin A 35 (Scheme 10).[171-
172] In the transformation of 30 into 87, the stereochemistry of the reduction probably 
reflects the result of a nonenzymatic partial epimerization at C-6 of  87 due to 
enolization of the keto group at C-1. 
 
Two alternative possibilities can be envisaged for the formation of validoxylamine 43, 
from 30 and 87 (Scheme 10). Either transamination of 30 would give valienamine 31, 
which would then reductively couple with 87 or, alternatively, 87 would be 
transaminated to give validamine 32, which would then couple with 30. However, 
circumstantial evidence in favor of the second of these two scenarios comes from 
experimental observations using feeding experiments. Finally, incorporation of the 
glucose moiety should be mediated by a glucosyl transferase enzyme. 
 
On the other hand, studies on Actinoplanes sp. have identified glutamate 88, a typical 
substrate of transaminases, as the most efficient nitrogen donor. Also aspartate 89 and 
the α-nitrogens of asparagine 91 and glutamine 90 were also found to be good nitrogen 
sources in glutamate-depleted cultures [173]. It should be indicated that glutamate, 
aspartate, glutamine and asparagine are interconected in typycal reactions of the 
aminoacids metabolism as indicated in Scheme 11. 
 
As we have previously indicated, the validamycin A fermentation also produces a 
number of minor components. Some of these, such as validamycins C (37), D (38), E 
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(39), and F (40), are derived from validamycin A 35. The formation of the validamycin 
congeners which differ from 35 in the structure of the second cyclitol moiety would 
require the transamination of other ketocyclitols, such as 6-hydroxyvalidamine 33 for 
validamycin B (36) and valiolamine (34) for validamycin G (41) (Scheme 12). 
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Scheme 3. Oxidative phase. Legend: a) Compounds. 65: Glucose-6-phosphate; 66: 
NADP+; 67: 6-Phosphoglucono--lactone; 68: NADPH; 69: 6-Phosphogluconate; 70: 
Ribulose-5-phosphate; b) Enzymes: i) Glucose-6-phosphate dehydrogenase[163]; ii) 6-
Phosphogluconolactonase [164]; iii) 6-Phosphogluconate dehydrogenase [165].  
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3.2.4. Biosynthesis of Acarbose. [176]  
 
With the exception of 2-epi-5-epi-valiolone (77) none of the ketocyclitols 5-epi-
valiolone (80), valienone (30), and validone (87) involved in the biosynthesis of the 
valienamine moiety of validamycins were incorporated (feeding experiments) into the 
valienamine moiety of acarbose. In consequence, the pathways in the formation of both 
metabolites seem to be substantially different. [177-178] 
 
In a first approach to the biosynthesis of acarbose, it is assumed that the first generate 
intermediate is deoxythymidine diphosphate (dTDP) acarviose (93). It should be 
pointed out that Thymidine diphosphate dTDP (92, see Scheme 13) misnamed 
deoxythymidine diphosphate [179] consists of a pyrophosphate group attached to the 
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nucleoside thymidine.[180]. This intermediate is able to tranfer the acarviosyl moiety to 
C6’ of maltose. It should be pointed out that acarbose is formed from maltotriose by 
two routes: (a) 60% of the acarbose is formed by attachment of maltose, produced by 
removing a glucose exclusively from the nonreducing end of maltotriose, to the 
pseudodisaccharide core unit. (b) The other 40% of acarbose is formed by direct 
attachment of maltotriose to the core unit followed by loss of the terminal glucose from 
the reducing end [181]. 
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Scheme 5. Transformation of 3-deoxy-D-arabino-heptalusonate-7-phosphate into 3-
dehydroquinate. 
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Scheme 6. Transformation of sedo-heptulose-7-phosphate 75 into valienone 30. 
 
A reasonable route for the formation of dTDP-acarviose (93) involves the introduction 
of the nitrogen atom into the deoxy sugar moiety via transamination of dTDP-4-keto-6-
deoxy-D-glucose (94) to dTDP-4-amino-4,6-dideoxy-D-glucose (95). This compound 
then forms a Schiff’s base with 2-epi-5-epi-valiolone (77) which undergoes 2-
epimerization, 5,6-dehydration and final imine double bond reduction to 93 (Scheme 
13). 
 
An alternative hypothetical pathway involves the reduction of the keto-sugar 77 to 1-
epi-valiol (99). Further activation of the C1 hydroxyl group as a phosphate (100) and 
subsequent nucleophilic displacement by the nitrogen of amino sugar 95 would afford 
pseudosaccharide 101. This compound, after epimerization at C2 and 5,6-dehydration 
would give dTDP acarviose (93) (Scheme 14)[182]. 
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Scheme 8. Proposed mechanism for the formation of compound 84 from 82. 
 
More recently and on the basis of genetic and biochemical studies, a new mechanism 
for the biosynthesis of acarbose has been postulated. The Acarbose gene cluster (Acb) 
[183-186] gene cluster, involved or proposed in the sequence, are also indicated 
(Schem15). It should be indicated that a gene family is a set of homologous genes 
within one organism. A gene cluster is part of a gene family. The size of gene clusters 
can vary significantly from a few genes to several hundred genes. Regardless of the 
similarity of the DNA sequence of each gene within a gene cluster, the resulting protein 
of each gene is distinctive from the resulting protein of another gene within the cluster. 
The Acb corresponds to the 25 known gene cluster from Actinoplanes sp. SE50/110 
identified and sequenced. Other Acb biosynthetic gene cluster from Streptomyces 
glaucescens has also been identified and sequenced.  
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Scheme 10. Biosynthesis of validoxylamine 43 from valienone 30. 
 
In this mechanism the cyclitol precursor, 2-epi-5-epi-valiolone (77), is phosphorylated 
to give 2-epi-5-epi-valiolone-7-phosphate (102) in a process mediated by the enzyme 2-
epi-5-epi-valiolone 7-kinase. Compound 102 is then epimerized at C2  to give 5-
epivalielone-7-phosphate (103). Further steps involving dehydration (104), carbonyl 
reduction and phosphorylations (105), nucleotidylation [187] (106) and final 
nucleophilic displacement by the nitrogen atom of 95,  would afford compound 93 
[188-191].  In Scheme 15 The transformation 105-106 constitutes a nucleotidylation 
reaction: the transfer of an entire nucleotidyl unit, rather than just a phospho group 
[192]. 
 17
 
O
O O
O
O
O
NH3
O
O
O
O
O
O
O
O
Transaminase
O
O
O
O
NH3
O
NH3
O
O
O
O
O
O
H2N
NH3
H2N
O
O
O
NH3
Oxalacetate
88 -ketoglutarate
89
90 88
91ATP AMP + PP
i)
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Scheme 14. Alternative biosynthesis of dTDP-acarviose 93. 
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Scheme 15. Revised proposal of the biosynthetic pathway to dTDP-acarbose 93. NDP = 
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3.2.5. Biosynthesis of Pyralomicins.  
 
The biosynthetic gene cluster for the biosynthesis of pyralomicin antibiotics (PrI) has 
been isolated, cloned and sequenced from Nonomuraea spiralis IMC A-0156 [193]. The 
41 kb (1000 base pairs) gene cluster contains 27 ORFs (the open reading frame –ORF- 
is the part of a reading frame that has the potential to code for a protein or peptide) 
[194-195] predicted to encode all of the functions for pyralomicin biosynthesis. This 
includes nonribosomal peptide synthetases (NRPS, Nonribosomal peptides (NRP) are a 
class of peptide secondary metabolites, usually produced by microorganisms. While 
there are a wide range of peptides that are not synthesized by ribosomes (the term 
nonribosomal peptide typically refers to a very specific set of these) and polyketide 
synthases (PKS) [196-197] required for the formation of the benzopyranopyrrole core 
unit. The PKS are a multi-domain enzyme complex involved in the biosynthesis of 
polyketides and fatty acids. The PKS genes for a certain polyketide are usually 
organized in one operon (an operon is a functioning unit of genomic DNA containing a 
cluster of genes under the control of a single promoter [198] ) in bacteria and in gene 
clusters in eukaryotes. The biosynthesis of nonribosomal peptides shows several 
similarities with the polyketide and fatty acid biosynthesis. As consequence, some 
nonribosomal peptide synthetases contain polyketide synthase modules for the insertion 
of acetate or propionate-derived subunits into the peptide chain [199-201]. Others 
enzymes such as four halogenases [202] an O-methyltransferase [203-205] and an N-
glycosyltransferase[206-207] necessary for further modifications of the core structure of 
pyralomicins have also been identified. In particular, the N-glycosyltransferase is 
involved in the transfer of either glucose or a pseudosugar (cyclitol) to the aglycone. 
 
The formation of the cyclitol moiety of pyralomicyns is depicted in Scheme 16. This 
pathway appears to be mediated through the actions of several enzymes including the 2-
epi-5-epi-valiolone synthase PrlA, a putative phosphomutase (PrlB), a cyclitol kinase 
(PrlU), two cyclitol dehydrogenases (PrlV and PrlW), and a 2-epi-5-epi-valiolone 
phosphate epimerase (PrlX). This cassette of genes shares high homology with the 
cyclitol biosynthetic genes from the salbostatin [208] and acarbose gene clusters. 
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On the other hand, the starting material for the biosynthesis of the aglycone portion of 
pyralomicin is the aminoacid L-proline and involves genes that share high identity with 
some related compounds. 
 
3.2.6. Biosynthesis of Salbostatin.  
 
In silico analysis of the putative biosynthetic gene cluster of salbostatin from 
Streptomyces albus ATCC 21838 revealed 20 open reading frames. The salbolstatins 
genes SalF, SalL, SalM, SalN, SalO, and SalR were found to be homologous to AcbR, 
AcbM, AcbL, AcbN, AcbO, and AcbP from the acarbose pathway, respectively (see 
above). That suggests that the biosynthesis of the aminocyclitol moiety of salbostatin 
may be very similar to that of acarbose (Scheme 17). 
 
Thus, 2-epi-5-epi-valiolone 77 is first converted to its activated form, 2-epi-5-epi-
valiolone 7-phosphate 102, by the action of the 2- epi-5-epi-valiolone 7-kinase (AcbM), 
Epimerization at the C-2 position by AcbO gives 5-epi-valiolone 7- phosphate 107. This 
compound is proposed to be converted to 5-epi-valiolol 7-phosphate 111 or valienone-
7-phosphate 103 which were dehydrated (from 111) or reduced (from 103) to 1-epi-
valienol 7-phosphate 112. From 112, 1-epi-valienol-l-phosphate 113, and then NDP-1-
epi-valienol 114 were successively formed. Condensation of NDP-1-epi-valienol 114 
with deoxyglucosamine 115 (biosynthesized from N-acetylglucosamine) may finally 
result in the formation of salbostatin-6’-phosphate 116 which is then converted into 
salbostatin 54. 
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Scheme 16. Proposed mode of formation of the cyclitol moiety of pyralomicins. Legend. 
77: 2-epi-5-epi-valiolone; 102: 2-epi-5-epi-valiolone-7-phosphate; 107: 5-epi-valiolone-
7-phosphate; 103: valienone-7-phosphate; 108: valienol-7-phosphate; 109: valienol-1-
phosphate; 110: NDP-valienol. 
 
4. Biological Activity of Carbasugars.  
 
As we have previously pointed out (see Introduction) and according to Prof. McCasland 
“pseudo-sugars may be found acceptable in place of corresponding true sugars to some 
but not all enzymes or biological systems, and thus might serve to inhibit growth of 
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malignant or pathogenic cells”.[209] For instance, it, may be indicated that synthetic 6a-
carba- -DL-fructopyranose was found to be almost as sweet as D-fructose. [210-212]  
 
In the context of enzymatic inhibition, [213] the structural similarity between true 
sugars and carbasugars can cause inhibition of enzymes involved in the digestion of 
carbohydrates which can lead to important consequences under medically point of view. 
For instance, the inhibition of carbohydrate digestive enzymes is considered a 
therapeutic tool for the treatment of type 2 diabetes.[214]. In the next paragraphs some 
applications of carbasugars and derivatives as enzymatic inhibitory agents wil be 
highlighted.  
 
4.1. Biological activity of Carbafuranoses. 
 
The carbocyclic analogue of 5-phosphoribosyl-1-pyrophosphate (cPRPP, Figure 17) is 
the only reported carbafuranose with significant biological activity.[215-217] This 
compound shows enzymatic inhibitory activity against the enzyme 5-phosphoribosyl R-
1-pyrophosphate (PRPP) synthetase [218-220] with values [221] Ki of 186 μM (human 
type PRPP synthetase) and a Ki of 3811 mM (Bacillus subtilis PRPP synthetase). The 
enzyme PRPP-synthetase converts ribose 5-phosphate into phosphoribosyl 
pyrophosphate (PRPP) (Scheme 18). The resulting PRPP acts as an essential component 
of the purine salvage pathway (used to recover bases and nucleosides that are formed 
during degradation of RNA and DNA) and the de novo synthesis of purines. Mutations 
that lead to super-activity (increased enzyme activity or de-regulation of the enzyme) 
result in purine [222] overproduction. Super-activity symptoms include, among others, 
neurodevelopmental disorders [223]. On the other hand there is evidence that the 
activity of PRPP synthetase is elevated in tumors. Then, inhibitors of this enzyme show 
antineoplastic activity [224-225]. 
 
  
Figure 17 
 
  
Scheme 18 
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Scheme 17. Proposed biosynthetic pathway for salbostatin.  
 
4.2. Biological Activity of Carbapyranoses.  
 
4.2.1. Cyclophellitol and derivatives.  
 
(+)-Cyclophellitol (5) was found to be a specific inhibitor of β-glucosidases (enzymes 
that hydrolyze glycosidic bonds to release nonreducing terminal glucosyl residues from 
glycosides and oligosaccharides [226]) [227-228] with potential inhibition of the human 
immunodeficiency virus (HIV) and with possible antimetastatic therapeutic activity 
[229-231]. Several unnatural cyclophellitol derivatives also show interesting biological 
properties. [232-125]. For instance, (1R,6S)-cyclophellitol 120 –which is its unnatural 
diastereomer- inhibits α-glucosidases [236-237] and cyclophellitol aziridines [238-241] 
121 are potent and selective irreversible inhibitors of retaining glycosidases (Figure 18).  
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Figure 18. Structures of cyclophellitol 5, (1R,6S)-cyclophellitol, 120, and cyclophellitol 
aziridines, 121. 
 
Several natural and synthetic epoxyquinones and epoxyquinols with structures related to 
both cyclophellitol and gabosines (see below) also show interesting biological 
properties. The chemistry and biological activities of these compounds have been 
described in an autoritative reviews and will not be considered here [59]. 
 
4.2.2. MK-7067, carba-galactopyranose, carba-glucopyranose, streptol and COTC.  
 
The unsaturated carbapyranose (+)-MK7067 6 exhibited an effective herbicidal activity 
[242]. Carba-α-D-galactopyranose (4) was found to have a low antibiotic activity 
against Klebsiella pneumonia MB-1264, [243] whereas the L-enantiomer is inactive 
[244]. 5a-carba-α-DL-glucopyranose ((±)-122, Figure 19) is a glucokinase (a 
monomeric cytoplasmic enzyme found in the liver and pancreas. Its main function is 
regulation of glucose levels in these organs [245-246] ) inhibitor. Carbasugar (±)-122 
and the β-anomer (±)-121 were used as synthetic analogs of glucose anomers to study 
the mechanism of glucose-stimulated insulin release by pancreatic islets [247]. It was 
found that alpha isomer (±)-122, but not the beta-isomer (±)-121, inhibited both 
glucose-stimulated insulin release and islet glucokinase activity in a concentration-
dependent manner. On the other hand, a cellobiose phosphorylase from Cellvibrio 
gilvuse recognizes only the beta-D-form of 5a-carba-glucopyranose (±)-121 [248]. 
 
  
Figure 19. Structures of -and -glucopyranose (only D-enantiomers are shown). 
 
Streptol (7) inhibited the root growth of lettuce seedlings at a concentration < 13 ppm. 
 
The 2-Crotonyloxy-(4R,5R,6R)-4,5,6-trihydroxycyclohex-2-enone, COTC (29) and 
derivatives have been shown to display notable toxicity towards a range of different 
cancer cell lines. The general mechanism for anti-cancer activity of COTC is depicted in 
Scheme 19 [249-253]. After conjugate addition of glutathione (-L-glutamyl-L-
cysteinylglycine, GSH. Glutathione S-transferases (GSTs) comprise a family of 
isozymes -enzymes that differ in amino acid sequence but catalyze the same chemical 
reaction- known for their ability to catalyze the conjugation of the reduced form of 
glutathione (GSH) to xenobiotic -foreign chemical substance found within an organism 
that is not normally naturally- to the enone moiety of 29, the resulting enol 123 
undergoes expulsion of crotonic acid to generate exocyclic enone 124. It should be 
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pointed out that the rate of formation of enol 123 is substantially increased by 
enzymatic catalysis via glutathione transferase (GST). Alkylation of intracellular 
proteins and/or nucleic acids by 124 then lead to cell death. Other processes may also 
contribute to the anti-cancer activity of this compound and derivatives.  For instance, 
the GSH conjugate 126, derived by trapping the exocyclic enone 124 with GSH, and 
bis-GSH adduct 127 are competitive inhibitor of human glyoxalase 1 (Glo1). This 
enzyme is vital for cell survival as part of a detoxification system for cytotoxic 2-
oxoaldehydes or other toxic species and they inhibitors have previously been 
demonstrated to have anti-cancer properties [254-255]. On these bases, it seems logical 
to have carried out extensive efforts for the synthesis of new analogues COTC [256-
264].  
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Scheme 19. Proposed mode of action of COTC and derivatives 
 
A key enzyme in the biosynthesis of clinically important aminoglycoside antibiotics 
such as neomycin, kanamycin and gentamicin, [265] among others, is 2-deoxy-scyllo-
inosose synthase (DOIS), which catalyzes the carbocycle formation from D-glucose-6-
phosphate 128 to 2-deoxy-scyllo-inosose (DOI, 129, Scheme 20, [266]). 
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Scheme 20. Transformation of D-glucose-6-phosphate into 2-deoxy-scyllo-inosose. 
 
5a-Carba-DL-glucose-6-phosphate (130) is an irreversible inhibitor of DOIS. The 
proposed reaction mechanism for this inhibitory action is shown in Scheme 21 [267]. 
Thus, after the initial oxidation at C4 and subsequent elimination of a phosphate, 
compound (±)-130 was converted within the enzyme into an α,β-unsaturated methylene 
cyclohexanone (±)-132. This α,β-unsaturated carbonyl intermediate is attacked by a 
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specific nucleophilic residue in the active site (Lys-141) through a Michael-type 1,4-
addition, resulting in the formation of compound 133. 
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Scheme 21. Mechanism of irreversible inhibition of DOIS by 5a-Carba-DL-glucose-6-
phosphate. 
 
4.2.3. Pericosines  and gabosines. 
 
Pericosines A-C (8-10) exhibited significant growth inhibition against several tumor 
cell lines. In particular, pericosine A (8) shows significant in vitro cytotoxicity against 
P388 lymphocytic leukemia cells [268] also showing significant in vivo tumor 
inhibitory activity. In additionn, pericosine A inhibited [271] the protein kinase EGFR 
(the epidermal growth factor (EGF) stimulates cell growth, proliferation, and 
differentiation by binding to its receptor EGFR. Human EGF is a 6045-Da protein with 
53 amino acid residues and three intramolecular disulfide bonds. Mutations that lead to 
EGFR overexpression or overactivity have been associated with a number of cancers. 
[269]) and topoisomerase II (topoisomerases are isomerise enzymes that act on the 
topology of DNA. Type II topoisomerases cut both strands of the DNA helix 
simultaneously in order to manage DNA. They use the hydrolysis of ATP, unlike Type I 
topoisomerases which are ATP-independent. [270]) Gabosine E (20) showed [273] a 
weak inhibitory effect on the cholesterol biosynthesis in cell line tests with HEP-G2 
(This line has been found to express a wide variety of liver-specific metabolic functions. 
Among these functions are those related to cholesterol and triglyceride metabolism live 
cells [272]). 
 
On the other hand, Gabosines A (15), B (16), F (21), N (18), and O (28) present DNA-
binding properties [274-275]. Gabosine C (17) is the known antibiotic KD16-U [276] 
and its crotonyl ester is the previously considered carbasugar COTC. Gabosine J (25) 
inhibits α-mannosidase, an enzyme involved in the cleavage of the alpha form of 
mannose, [277] and some derivatives such as -gabosinol 134 and -gabosinol 135 
inhibit β-galactosidase and β-glucosidase respectively (Figure 20) [278]. 
 
Some compounds structurally related with gabosines also show interesting biological 
properties. For instance, compound (+)-136 has been reported [279] that is a cytotoxic 
and potential contraceptive agent. On the other hand, nigrospoxydon A (137) shows 
activity against Staphylococcus aureus ATCC 25923, a clinical isolate with the 
designation Seattle 1945 that is used as a standard laboratory testing control strain [280]. 
It has also been published that the closely related esters (−)-138 and epoxydine B (139) 
display antibacterial, antifungal, and antialgal activities (Figure 20) [281]. The synthetic 
compound (+)-RKTS-33 (140) has inhibitory activity toward death receptor-mediated 
apoptosis [282-283]. The racemate of compound 141 is a nuclear factor-κB (NF-κB or 
nuclear factor kappa-light-chain-enhancer of activated B cells, is a protein complex that 
controls transcription of DNA, cytokine production and cell survival.[284-285]) 
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inhibitor and therefore a suitable candidate as antiinflammatory and anticancer agent 
[286]. 
 
Finally, compound 142 shows [287] synergetic effect with cisplatin against lung cancer 
cell line A549 (adenocarcinomic human alveolar -terminal ends of the respiratorytree-
basal epithelial cells [288], through the inhibition of GSTM1 (Glutathione S-transferase 
Mu 1 -gene name GSTM1- is a human glutathione S-transferase [289]. 
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Figure 20. Some biologically active gabosine derivatives.  
 
4.2.4. Carbaglycosides. 
 
O-linked alkyl carba-β-D-glycosides 143 and 144 (Figure 21) have been shown [290]  
to be useful as primers for biocombinatorial glycosylation involving efficient uptake in 
B16 mouse melanoma cells, the most frequently used murine melanoma model 
[291].Uptake of the carbaglycosides resulted in β-galactosylation and subsequent 
sialylation of the galactose residues incorporated, to give rise to glycosylated products 
having a glycan similar to that in ganglioside GM3, a type of ganglioside, molecule 
composed of a glycosphingolipid with one or more sialic acids linked on the sugar chain. 
The letter G refers to ganglioside, and M is for monosialic acid as it has only one sialic 
acid residue. The numbering is based on its relative mobility in electrophoresis among 
other monosialic gangliosides. Recently, gangliosides have been found to be highly 
important molecules in immunology. Natural and semisynthetic gangliosides are 
considered possible therapeutics for neurodegenerative disorders [292-293]. This 
indicate that carbasugars can be stable and versatile building blocks for the 
biocombinatorial synthesis using a living cell. In addition, a strong and specific 
inhibition of β-galactosidase (bovine liver) was found for dodecyl 5a-carba-β-D-
galactopyranoside (144). 
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Figure 21. Structures of carba-β-D-glycosides 143 and 144.  
 
In addition, more complex carbaglycosides have interesting biological activities. 
Synthetic carbaxylosides of coumarins, i.e., (+)-145 or (-)-145, have significant 
potential as oral antithrombotic agents [294], and a 5a-carba analogue of 
glucotropaeolin, (±)-146, was shown to display a good inhibition power [295] against 
myrosinase, the only known enzyme found in nature that can cleave a thio-linked 
glucose [296]. (Figure 22). 
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Figure 22. Structures of carba-glycosides 145 and 146. 
 
4.2.5. Carbanucleotides. 
 
Some synthetic carbasugar-nucleotide displayed biological activity as 
glycosyltransferase inhibitors. For instance, uridine-5′-(5a-carba-α-D-galactopyranosyl 
diphosphate) 147 (Figure 23), the carbocyclic analog of UDP-galactose, exhibits 
inhibitory activity of β-(1→4) galactosyltransferase from bovine milk [297]. 
 
On the other hand, the carbocyclic analogue of GDP-fucose, consisting of 5a-carba-β-L-
fucopyranose 148 [298], was found to be a competitive inhibitor of fucosyltransferases, 
key enzymes in the biosynthesis of the Lewis-x determinant. Interestingly, the carba-
fucose analogue 148 showed a Ki value similar to that observed for the GDP-fucose 
indicating that the ring oxygen of fucose is not critical for the recognition of GDP-Fuc 
by the enzyme, albeit it is essential for the transfer to occur [299]. 
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Figure 23. Structure of carbanucleotides 147 and 148.  
 
4.2.6. Aminocarbasugars. 
 
Amino carbasugars [300] are the most important and appealing carbapyranose 
derivatives from a biological standpoint.  
 
4.2.6.1. Valienamine, validamine, hydroxyvalidamine, valiolamine and derivatives. 
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Simple aminocarbasugars such as valienamine (31), validamine (32), 
hydroxyvalidamine (33), and valiolamine (34) appeared to be active against several 
sugar hydrolases [301-302]. Valienamine, validamine and hydroxyvalidamine were 
reported as microbial oligosaccharide α-glucosidase inhibitors [303-306]. The α-
galacto-, β-gluco-, and α-mannovalidamine analogues 149-151 (Figure 24) have been 
prepared and their glycosidase activity tested [307-309]. These compounds, however, 
displayed moderate activity as glycosidase inhibitors when compared with (α-gluco-
validamine. Converselely, valiolamine (34) has more potent α-glucosidase inhibitory 
activity against porcine intestinal sucrase, maltase, and isomaltase than the rest of the 
aminocarbasugars [310]. That is why series of N-substituted valiolamines were 
synthesized, resulting in the preparation of the glycohydrolase inhibitor voglibose (152) 
[311-313]. Voglibose was launched as an antidiabetic agent in 1994 to improve 
postprandial hyperglycemia in diabetes mellitus [314-316]. Voglibose inhibits 
disaccharidases competitively, suppressing the elevation of the blood glucose 
concentration after oral sucrose, maltose, or starch administration, but not after oral 
glucose, fructose, or lactose intake.  
 
  
Figure 24. Structures of α-galacto-, β-gluco-, and α-mannovalidamine analogues (149-
151) and Voglibose (152). 
 
Moreover, carbocyclic analogues of glycosylamides [317], which contain the 5a-carba-
D-hexopyranose residues (Figure 25), have also been synthesized. 5a-Carba-β-
glucopyranosyl- and 5a-carba-β-galactopyranosyl-amides 153 and 154 have been shown 
to be potent immunomoduladors, comparable to the true sugars [318], suggesting that 
the glycolipid analogues may provide appropriate model compounds for biochemical 
studies in glycolipid chemistry. On the other hand, the glycosidase inhibitory effects of 
1,2-bis-epi-valienamine 155 and 1-epi-2-acetamido-2-deoxy-valienamine 156 (Figure 
25) have been investigated. 1,2-bis-epi-Valienamine 155 acts as a -mannosidase [319] 
inhibitor whereas 2-acetamido-2-deoxy-1-epi-valienamine 156 has been shown [320] to 
inhibit various -hexosaminidases, enzymes involved in the hydrolysis of terminal N-
acetyl-D-hexosamine residues in N-acetyl-β-D-hexosaminides [321-323]. 
 
  
Figure 25. 5a-Carba-β-glucopyranosyl- and 5a-carba-β-galactopyranosyl-amides. 
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A serie of N-linked carbocyclic analogues of glycosylceramides, structurally related to 
glycosphingolipids and glycoglycerolipids, have also been synthesized by replacing the 
sugar residue with either saturated [324] (157, 158, Figure 26) or unsaturated [325] (159, 
160, Figure 26) 5a-carba-D-gluco- or 5a-carba-D-galactopyranoses, respectively. 
Compounds 157 and 158 are mild immunomodulators and possess a mild inhibitory 
activity against gluco- and galactocerebrosidases, whereas the unsaturated gluco-159 
and galacto-160 analogues were shown to be very potent and specific of gluco- and 
galactocerebrosidase inhibitors, respectively, thus showing the critical role played by 
the C4 configuration for specificity in inhibition. 
 
  
Figure 26. N-linked carbocyclic analogues of glycosylceramides 157-160. 
 
Various N-alkyl- and N,N-dialkyl-β-valienamines were synthesized and testing as 
glycosilases inhibitors [326-329]. For instance, N-benzylation of valienamine improves 
significantly they inhibitory activity toward α-glucosidases [330]. In this way, 91 pure 
N-alkylated valienamines 161 (Figure 27) prepared using solid-phase synthesis 
methodology are new -glucosidase inhibitors, being most of them more potent than 
valienamine [331]. On the other hand, the spiroaziridines and spirodiaziridines 162 and 
163 were prepared and evaluated as glycosidase inhibitors against β-glucosidases from 
almonds, β-glucosidase from Caldocellum saccharolyticum, and α-glucosidase from 
yeast with poor results compared with the cyclopentylamine 164 (Figure 27) [332]. 
 
Two isomeric bicyclo[4.1.0]heptane 165 and 166 (Figure 27) have been synthesized and 
evaluated against α-galactosidase enzymes from coffee bean and E. coli [333]. The 
activity of the glycosyl hydrolase family GH27 enzyme (coffee bean) was competitively 
inhibited by the 1R,6S-amine with a Ki value of 0.541 μM. The E. coli α-galactosidase 
exhibited a much weaker binding interaction with the 1R,6S-amine (IC50 = 80 μM). The 
diastereomeric 1S,6R-amine bound weakly to both galactosidases, (coffee bean, IC50 = 
286 μM) and (E. coli, IC50 = 2.46 mM). 
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Figure 27. Alkylated valienamine derivatives, spiroaziridines 162, spiroazirinas 163, 
cyclopentylamine derivative 164 and bicyclo[4.1.0]heptane  derivatives 165 and 166. 
 
N-Octyl-β-valienamine derivative 167 (Figure 28) is a potent and specific inhibitors of 
β-glucocerebrosidades (IC50 = 3 x 10-8 M). On the contrary, galacto derivative 168 did 
not show any improvement in potency. Additionally, it was later demonstrated that 167 
and 168 are potent competitive inhibitors of human β-glucosidase and human β-
galactosidase, respectively.  
 
  
Figure 28. N-Octyl--valienamine derivatives. 
 
These activities suggest that carbasugar derivatives 167 and 168 work as chemical 
chaperones,[334-337] to accelerate transport and maturation of mutant forms of enzyme 
proteins and therefore may be useful for certain patients with β-galactosidosis and 
potentially other lysosomal storage diseases [338-350]. It should be opportune at this 
point clarify the concept of chemical chaperone [351-353]. Pharmacological or 
molecular chaperone therapy is among the newest therapeutic ideas for lysosomal 
storage diseases. Lysosomes are enzymes within cells that digest large molecules and 
pass the fragments on to other parts of the cell for recycling. This process requires 
several critical enzymes. If one of these enzymes is defective, because of a mutation, the 
large molecules accumulate within the cell, eventually killing it. Pharmacological 
chaperones are small molecules that specifically bind to and stabilize the functional 
form or three-dimensional shape of a misfolded protein in the endoplasmic reticulum 
(ER) of a cell. When misfolded due to a genetic mutation, the enzyme is unable to adopt 
the correct functional shape and, in consequence, the enzyme activity is reduced. The 
binding of the chaperone molecule helps the protein fold into its correct three-
dimensional shape. Pharmacological chaperone therapy is in early stage clinical trials 
for disease such as Fabry (a rare genetic lysosomal storage disease. Fabry disease can 
cause a wide range of systemic symptoms such as pain, kidney complications, high 
blood pressure, cardiomyopathy, fatigue, vertigue, nausea, diarrhea, etc) and Gaucher 
Type I (a genetic disorder in which glucocerebroside accumulates in cells and certain 
organs. The disorder is characterized by bruising, fatigue, anemia, low blood platelet 
count and enlargement of the liver and spleen. It is caused by a hereditary deficiency of 
the enzyme glucocerebrosidase which acts on glucocerebroside. When the enzyme is 
defective, glucocerebroside accumulates, particularly in white blood cells and especially 
in macrophages (mononuclear leukocytes). 
 
In the search for different sugar hydrolase inhibitors, 5a-Carba-α-DL-fucopyranosyl 
amine [354-355] ((±)-169) and 5a-carba-β-L-fucopyranosylamine (170) [356] were 
prepared. These compounds have been shown to be strong inhibitors of α-L-fucosidase. 
α -Fucosidase inhibitors are interesting because they are potential candidates for cancer 
and HIV drugs, due to their inhibitory effect on the extracellular matrix secreted 
fucosidases [357]. Different N-substituted derivates of (±)-169 were prepared. The 
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inhibitory activity was increased by incorporation of alkyl and phenylalkyl groups into 
the amino function of the parent (±)-169. The change of the N-alkyl substituents, from 
ethyl on 171a to nonyl on 171e, improved the inhibitory power. The n-octyl derivate 
(171d) was found to be the strongest inhibitor of α-L-fucosidase (bovine kidney) more 
potent (Ki = 0.016 μm) than deoxyfuconojirimicin (Ki = 0.031 μm), the most powerful 
mammalian α-L-fucosidase inhibitor identified [358]. In a similar manner, chemical 
modifications of 170 generated N-substituted derivatives (±)-172a-g, which were found 
to be very strong β-galactosidase as well as β-glucosidase inhibitors with no specificity 
associated with the 4-epimeric structures. This inhibitory activity appeared attributable 
to D-enantiomers exclusively, that is, N-alkyl-6-deoxy-5a-carba-β-D-
galactopyranosylamines (D-172) [359]. (Figure 29). 
 
  
Figure 29. Carba-fucopyranosyl amines 169-172. 
 
Carbasugar derivatives have also been envisaged to play roles in elucidating and 
controlling other biological events that involve sugar moieties. This includes the 
synthesis of analogues of enzyme substrates, which were modified by replacing part of 
their structures with carbasugar units and which were expected to be used in the 
elucidation of the mode of action of sugar transferases [360]. These analogues have 
been recognized as good substrates, thus showing that the ring oxygen in the acceptor is 
not involved in the specific recognition by the enzyme. For instance, bovine β-(1→4)-
galactosyltransferase was tested with α-galacto- (173), α- and β-manno- (174 and 175), 
and α- and β-gluco- (176 and 177) 2-acetamido-2-deoxy-5a-carba-DL-hexopyranoses 
[361]. Of these compounds, only 176 and 177 behave as galactosyl acceptors. The 
reactions afforded disaccharides 178 and 179, but half of the material remained 
unreacted, suggesting that only the D-enantiomers behaved as acceptors. These results 
indicate that the ring oxygen atom is not used for specific recognition by bovine β-
(1→4)-galactosyltransferase (Figure 30). 
 
4.2.6.2. Validamycins, salbostatain, acarbose, amylostatins, adiposins, oligostatins, 
tetrastins and related compounds. 
 
Validamycins 35-42 and salbostatin (54) have been reported to be mechanistically 
unique antifungal agents [362-366]. Validamycin A (35), the most active compound of 
the complex, is a fungicida that inhibits trehalases, enzymes that carry out the 
degradation of the non-reducing disaccharide trehalose [367-369] in plants, insects, and 
fungi as well as enhance trehalose accumulation in transgenic plants. It is widely used in 
rice-producing countries in Asia to control sheath blight disease of the rice plants 
caused by the fungus Rhizoctonia solani [370-384]. 
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Figure 30. Carbasugars as sugar transferases. 
 
Validamycin A is able to control the spread of the pathogen by inhibiting specifically 
the hyphal (a long, branching filamentous structure of a fungus, oomycete, or actinobacterium  [385]) 
extension without affecting the specific growth rate. It means Validamycin A is 
effective against Pellicularia sasakii and Rhizoctonia solani in plants, but only 
decreases their virulence instead of exhibiting a fungicidal effect [386-389]. Further 
extensive studies on the mechanism of action of validamycin in controlling the hyphal 
extension have been carried out by several research groups, and it seems to be related to 
the anti trehalase activity [390-392] of the carba-disaccharide validoxylamine (43) [393]. 
For the purpose of developing more potent trehalase inhibitors, several pseudo-
trehalosamines, such as 180 and 181, as well as dicarba analogues of trehalose, 182-184, 
composed of valienamine, validamine, and valiolamine moieties, were synthesized and 
they showed to possess strong inhibitory activity against trehalase (Figure 31) [394-396]. 
 
O
HO
HO
NH2
O
OH
OH
OH
OH OH
180
O
HO
HO
NH2
O
OH
OH
OH
OH OH
181
O
HO
HO
OH
NH OH
OH
OH
OH OH
182
HO
HO
OH
NH OH
OH
OH
OH OH
183
O
HO
HO
OH
NH OH
OH
OH
OH OH
184
HO HO
  
Figure 31. Carbasugars 180-184 with anti-tetrahalase activity 
 
Many members of the carba-oligosaccharidic group, e.g., acarbose (46), amylostatins 
(50), adiposins (51), oligostatins (52), and trestatins (53), are known to display potent α-
glucosidase inhibitory effects. Among these active metabolites, acarbose is of 
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considerable pharmacological interest. In addition to its α-glucosidase activity, acarbose 
also displays potent inhibitory activity against sucrase, maltase, dextrinase, and 
glucoamilase. This pronounced inhibitory effect has resulted in its use as a clinical drug 
for the treatment of type II non-insulin-dependent diabetes and, in some countries, 
prediabetes in order to enable patients to better control blood sugar contents while living 
with starch-containing diets. It is a starch blocker, and inhibits α-glucosidase, an 
intestinal enzyme that releases glucose from larger carbohydrates. Inhibition of these 
enzyme systems reduces the rate of digestion of complex carbohydrates. Less glucose is 
absorbed because the carbohydrates are not broken down into glucose molecules. 
Interestingly, individual members of different series of carba-oligosaccharides 
deactivate α-amylase and sucrase quite differently. Thus, whereas amylase inhibition is 
maximum with homologues of four and five glucose units, the greatest sucrase 
inhibition is caused by acarbose containing two glucose residues [397]. 
 
Adiposins (51) have exhibited potent inhibitory activities against α-glucoside 
hydrolases such as salivary and pancreatic α-amylases, and intestinal disaccharidases, 
such as sucrase, maltase, and isomaltase [398]. They have also showed antimicrobial 
activities against some Gram positive bacteria, Gram negative bacteria, some anaerobic 
bacteria, and some phytopathogenic fungi, and also showed a synergistic effect on the 
antibacterial activity with some maltooligosaccharides [399]. 
 
Oligostatins (52) exhibited not only strong α-amylase inhibitory activity but also they 
are active against Gram negative bacteria, while Gram positive bacteria are not affected 
[400]. 
 
The acarviosine, which is the core structure of acarbose and related carba-
oligosaccharides α-amylase inhibitors, is the responsible of their glycosidase inhibitory 
activities due to the valienamine portion mimics the glucopyranosyl cation intermediate 
at the active site for hydrolysis of α-glucosides in the acarviosine moiety. Thereupon, 
several chemically modified acarviosin analogues, 185-190, have been prepared and 
their glycosidase inhibitory activities were tested [401-404]. The results showed that the 
4-amino-4,6-dideoxy moiety could be replaced by other simple structures, such as 1,6-
anhydrohexoses, without losing its inhibitory power against α-glucosidase. However, 
modification of the valienamine portion, in order to mimic each substrate structure, did 
not result in any inhibitory activity against the targeted enzyme; see, for instance, 
compounds 189 and 190 for β-glucosidase and α-mannosidase activities, respectively 
(Figure 32). 
 
Carbatrisaccharide 191, an analogue of the “trimannosyl core” which frequently occurs 
in biologically important glycoconjugates [405-406], was found [407] to be fully active 
as an acceptor for N-acetylglucosaminyltransferase-V, both with the enzyme isolated 
from hamster kidney and with the one cloned from rat kidney. The kinetic parameters 
were functionally equivalent with those of the true trisaccharide. A preparative 
glycosylation reaction was performed using 191 as the acceptor with the cloned rat 
kidney enzyme. A tetrasaccharide formed by the addition of a Glc pNAc residue (192) 
was the sole product detected (Scheme 22). 
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Figure 32. Acarviosine analogues 185-190. 
 
  
Scheme 22. Carbatrisaccharides 191 and 192. 
 
Fucosyl and sialyl transferasas are involved in the synthesis of Sialyl Lewis-x, one of 
the most important blood group antigens, which is a tumor-associated tetrasaccharide, 
and ligand of E-selectin-mediated inflammatory extravasation of granulocytes and 
monocytes [408]. Fucosyl and sialyl transferases are involved in the last steps of the 
biosynthesis of Lewis oligosaccharide antigens by transferring α-fucopyranosyl residues 
[409-411]. Therefore, an area of interest is the design of potential inhibitors of these 
enzymes involved in the assembly of the Sialyl Lewis-x structure. In the search for 
inhibitors of the biosynthesis of Lewis oligosaccharide antigens, the synthesis of 
carbasugar analogues of the disaccharide fragment highlighted in Figure 33 was carried 
out by Ogawa et al [412-413]. They prepared ether- and imino-linked N-acetyl-5a´-
carba-β-lactosaminides and -isolactiminides, and tested them against fucosyltransferases. 
Biological assays showed that compounds 193a and 193b (Figure 33) are acceptor 
substrate for human-milk α-(1 3/4)-fucosyltransferase with kinetic parameters 
comparable to those observed for standard true disaccharides. Small-scale enzymatic 
synthesis was carried out by treatment of 193a and 193b with GDPfucose and milk 
fucosyltransferase which resulted in the conversion into the corresponding 
trisaccharides (by fucosylation at O3). Interestingly, compounds 194a and 194b were 
neither acceptors nor inhibitors for milk fucosyltransferase, suggesting that α-(1→4) 
transfer is not possible. The milk preparation contains a mixture of two different [α-
(1→3/4)- and α-(1→3)-] fucosyl transferase enzymes. These enzymes were separated, 
and it was shown that both forms utilized compounds 193a and 193b as acceptor 
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substrates, whereas 194a and 194b were not. This was the first demonstration of a 
specific substrate for a α-(1→3)-fucosyltransferase. 
 
In contrast with these results, screening carried out on isomeric octyl 5a-carba-β-
lactosaminide (195b) and isolactosaminide (196b) (where the carbasugar unit is at the 
reducing end) showed that both compounds were good substrates for α-(1→3)-
fucosyltransferase V (human recombinant, Spodoptera frugiperda) as well as α-(2→3)-
(N) sialyltransferase (rat, recombinant, Spodoptera frugiperda) when compared to the 
parent compounds 195a and 196a [414]. 
 
The inhibitory activity of four new carbadisaccharides (ether-linked methyl 5a’-carba-β-
lactoside (197a) and imino-linked methyl 5a’-carba-β-lactoside (197b), methyl N-
acetyl-5a’-carba-β-lactosaminide (197c), and methyl N-acetyl-5a’-carba-β-
isolactosaminide (198)) toward rat recombinant α-(2→3)-sialyl and rat liver α-(2→6)-
sialyl transferases with the presence of 4-methylumbellipheryl-labeled Lac-NAc as an 
acceptor substrate was evaluated [415]. Compounds 197a, 197b, and 198 showed more 
inhibition for α-(2→3)-sialyltransferase than for α-(2→6)-sialyltransferase. In addition, 
the enzyme-inhibition assays showed that compound 197b possess potent and specific 
inhibitory activity toward rat recombinant α-(2→3)-sialyltransferase. Moreover, 
compounds 197b (Km) = 185 μM) and 198 (Km = 245 μM) presented IC50 values similar 
to that for the acceptor (Km = 264 μM) toward α-(2→3)-sialyltransferases, whereas 
compound 133c displayed less inhibition (Km = 419 μM). Surprisingly, compound 197c, 
which was expected to inhibit both enzymes, did not show any appreciable inhibition 
toward any of them. The authors concluded from this study that the imino function 
enhances affinity for sialyltransferases but that when two nitrogen atoms exist, the 
enzymes maintain an equilibrium of interaction between them. They also established 
that a carbagalactose residue in carbadisaccharides may bind to sialyltransferases, but 
without the transfer of sialic acid. 
 
4.2.6.3. Pyralomicins. 
 
The pyralomicins 55-58 show activity against various bacteria, particularly strains of 
Micrococcus luteus, an opportunistic Gram-positive bacterium. The antibacterial 
activity of the pyralomicins appears to be dependent upon the number and the position 
of chlorine atoms within the molecules and the nature and methylation of the glycone 
[416]. That suggests a role for the cyclitol moiety in the antimicrobial activity.  
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Figure 33. Carbasugars disaccharide analogues as inhibitors of fucosyl- and sialyl 
transferases. 
 
5. Conclusions. 
 
More than four decades have already elapsed since the first synthesis of a carbocyclic 
analogue of a carbohydrate: a carbasugar. Because these compounds enjoy enhanced 
chemical stability, the prediction was that these new compounds could replace 
carbohydrates in their interaction with enzymes thus showing important biological 
properties. This prediction has been amply confirmed and several biologically active 
natural products containing carbasugars moieties have been discovered and their 
biosynthesis, synthesis and biological properties were objective of different 
authoritative research. In addition, many synthetic analogues of these natural products 
have been synthesized in the search for improved biological properties. It seems fair to 
predict that the future holds considerable promise for advances in this area. 
 37
 
6. Acknowledgments. 
 
One of us (S.R.) thanks Fundación Ramón Areces (Spain) for a post-doctoral fellowship. 
 
Conflict of Interest. 
 
The authors declare that there is not conflict of interests regarding the publication of this 
paper.   
 
                                                 
7. References. 
 
 
1. de Paz, J. L.; Seeberger, P. H. Recent advances in carbohydrate microarrays. QSAR Comb. Sci. 
2006, 25, 1027-1032. 
2  Miljkovic, M. in Carbohydrates. Synthesis, Mechanism and Stereoelectronic Effects. Springer, 
2010. 
3. Stick, R. V.; Williams, S. J. in Carbohydrates: The Essential Molecules of Life. Second Edition. 
Elsevier, 2009. 
4.  Carbohydrate Chemistry and Biochemistry: Structure and Mechanism. RSC. First Edition: 
Sinnott, M. ed., 2007. Second Edition: Sinnott, M. ed., 2013. 
5. Carbohydrate Chemistry. Chem. Rev. 2000, 100, Issue 12. Bashkin, J.K. ed 
6. Modern Synthetic Methods in Carbohydrate Chemistry. From Monosaccharides to Complex 
Glycoconjugates. Werz, D.B.; Vidal, S. eds., Wiley, 2013 
7. Carbohydrate Chemistry. Proven Synthetic Methods. CRC Press. Taylor & Francis Group. Vol. 
1: Kovac, P. ed., 2011. Vol. 2, van der Mare, G; Coreen, J. eds., 2014. Vol. 3: Roy, R.; Vidal, S. 
eds., 2015.  
8  Recognition of Carbohydrates in Biological Systems. Part A: General Procedures. Lee, Y.C.; 
Lee, R.T. eds. Methods in Enzymology. Vol. 362. Academic Press, 2003. Part B. Specific 
Applications. Lee, Y. C.; Lee, R. T. eds. Methods in Enzymology. Vol. 363. Academic Press, 
2003. 
9. Carbohydrate Recognition. Biological Problems, Methods and Applications. Wang; B.; Boons, 
G. J. eds., Wiley, 2011. 
10. Carbohydrates as Drugs. Topics in Med. Chem., Vol. 12; Seeberger, P.H.; Rademacher, Ch. eds., 
Springer, 2014. 
11. Carbohydrates in Drug Design and Discovery, Jiménez-Barbero, J.; Cañada, J.; Martín-
Santamaría, S. eds. RSC: Drug Discovery Series. Vol. 43, 2015. 
12. Chem. Rev. 2002, 102, Issue 2. Dwek, R.A.; Bothers, T.D. eds. 
13. Lis, H.; Sharm, N. Lectins: Carbohydrate-Specific Proteins that Mediate Cellular Recognition. 
Chem. Rev. 1998, 98, 637-674. 
14. Campo, V. L.; Aragón-Leoneti, V.; Teixeira, M. B. M.; Carvalho, I. Carbohydrates and 
glycoproteins: cellular recognition and drug design. New. Develop. Med. Chem., 2010, 1, 133-
151. 
15. Kiessling, L. L.; Grim, J. C. Glycopolymer probes of signal transduction. Chem. Soc. Rev. 2013, 
42, 4476-4491. 
16. Ruan, Y. L. Sucrose metabolism: gateway to diverse carbon use and sugar signalling. Annu. Rev. 
Plant Biol. 2014, 65, 33-67. 
17. Liung, K.; Nembauser, J. L.; Perata, P. New mechanistic links between sugar and hormone 
signalling networks. Curr.Opp. Plalnt Biol. 2015, 25, 130-137. 
18. Rini, J. M.; Leffer, H.: Carbohydrate Recognition and Signaling in Functioning of 
Transmembrane receptors in Signaling Mechanism. Cell Signaling Collection. Bradshaw, R.; 
Dennis, E. A. eds., Academic Press, 2011. Chapter 13, p. 341-347. 
19. The therapeutic potential of glycoconjugates has been described in: Doores, K. J.; Gamblin, D. 
P.; Davis, B. G. Exploring and exploiting the therapeutic potential of glycoconjugates Chem. Eur. 
J., 2006, 12, 656-665. 
20. The concept of “Medicinal Glycoscience” was developed in: Koeeler, K. M.; Wong, C. H. 
Emerging themes in medicinal glycoscience. Nat. Biotech. 2000, 18, 835-841. 
 38
                                                                                                                                               
21. Keding, S. J.; Danishefsky, S. J.: Synthetic Carbohydrate-Based Vaccines in Carbohydrate-
Based Drug Discovery. Wong, C. H. ed., Wiley, 2003, p. 381-406. 
22. Hecht, M. L.; Stallforth, F.; Silva, D. V.; Adibekian, A.; Seeberger, P. H. Recent advances in 
carbohydrate-based vaccines. Curr. Opinion Chem. Biol. 2009, 13, 354-359. 
23. Morelli, L.; Poletti, L.; Lay, L. Carbohydrates and Immunology: Synthetic Oligosaccharide 
Antigens for Vaccine Formulation. Eur. J. Org. Chem. 2011, 5723-5777. 
24. Bathia, S.; Dimde, M.; Hazg, R. Multivalent glycoconjugates as vaccines and potential drug 
candidates. Med.Chem.Med. Comm. 2014, 5, 862-878. 
25. Danishefsky, S. J.; Allen, J. R. From the laboratory to the clinic: a retrospective on fully 
synthetic carbohydrate-based anticancer vaccines. Angew. Chem. Int. Ed. Engl. 2000, 39, 836-
863. 
26. Sialyl Lewis X is a tetrasaccharide that is usually attached to O-glycans on the surface of cells. It 
is known to play a vital role in cell-to-cell recognition processes.  See: Syalo Glyco Chemistry 
and Biology. Part I: Biosynthesis, Structural Diversity and Sialoglycopathologies. Part II: Tools 
and Technique to Identify and Capture Sialoglycans. Gerardy-Schahn, R.; Delamoy, P.; von 
Itzsein M. eds. Topics in Current Chem., Vols. 366 and 367. Springer, 2015. 
27. Pudelko, M.; Bull, J.; Kunz, H. Chemical and chemo-enzymatic synthesis of glycopeptide 
selectin ligands containing sialyl Lewis X structures. ChemBioChem 2010, 11, 904-930. 
28. Kaila, N.; Thomas IV, B. E. Design and synthesis of sialyl Lewisx mimics as E- and P-selectin 
inhibitors. Med. Res. Rev. 2002, 22, 566-601. 
29. Biology of Inositols and Phosphoinositides. Subcellular Biochemistry. Vol. 39; Majunder, A. L.; 
Biswass, B. B. eds. Springer, 2006. 
30. Kukisis, A. in Inositol Phospholipid Metabolism and Phosphatidyl Inositol Kimases. Laboratory 
Techniques in Biochemistry and Molecular Biology. Vol 30. Pillai, S.; Van der Viet, P. C. 
Editors Series. Elsevier 2003. See in particular Chapter 5, p. 253-334. 
31. Glycosylphosphatidylinositols (GPI) Anchoring of Proteins. The Enzimes. Vol. XXVI Menon, A. 
K.; Orlean, P.; Kinoshita, T.; Tamanoi, F. eds. Elsevier, 2009. 
32. GPI Membrane Anchors. The much needed link. Dangerfield, J. A. ed. Metamer, Ch. co-ed. 
Bentham, 2010. 
33. Vilotijevic, I.; Gutze, S.; Seeberger, P. H.; Silva, D. V.: Chemical Synthesis of GPI Anchors and 
GPI Anchored Molecules. Modern Synthetic Methods in Carbohydrate Chemistry. Werz, D. B.; 
Vidal, S. eds.; Wiley, 2014; p. 335-372. 
34. Zurzolo, Ch.; Simons, K. Glycosylphosphatidylinositol-anchored proteins. Membrane, 
organization and transport. Biochim. Biophys. Acta, 2015. In press. DOI 
10.1016/j.bbamem.2015.12.018. Reference BBAMEM 82077. 
35. Boons, G. H.; Hale, K. J. in Organic Synthesis with Carbohydrates.. Wiley-Blackwell, 2000. 
36.  Carbohydrates Tools for Stereoselective Synthesis. Boysen, M. M. K. ed., Wiley, 2013. 
37. Sears, P.; Wong, C. H. Carbohydrate mimetics: a new strategy for tackling the problem of 
carbohydrate-mediated biological recognition. Angew. Chem. Int. Ed. 1999, 38, 2301-2324. 
38. Gruper, S. A. W.; Locardi, E.; Lohof, E.; Kessler, H. Carbohydrate-Based Mimetics in Drug 
Design: Sugar Amino Acids and Carbohydrate Scaffolds. Chem. Rev. 2002, 102, 491-514. 
39. Koester, D. C.; Holkerbrink, A.; Werz, D. B. Recent advances in the synthesis of carbohydrate 
mimetics. Synthesis 2010, 3217-3242. 
40. Cipolla, L.; Peri, F. Carbohydrate-based bioactive compounds for medicinal chemistry 
applications. Mini-Rev. Med. Chem. 2011, 11, 39-54. 
41. Joint Commission on Biochemical Nomenclature (A. D. McNaught) Pure Appl. Chem. 1996, 68, 
1919-2008.  
42. Arjona, O.; Gómez, A. M.; López, J. C.; Plumet, J. Synthesis and Conformational and Biological 
Aspects of Carbasugars. Chem. Rev. 2007, 107, 1919-2036. 
43. Plumet, J.; Gómez, A. M.; López, J. C. Synthesis of carbasugars based on ring closing 
metathesis: 2000-2006. Mini-Rev. Org. Chem. 2007, 4, 201-216. 
44. Jarosa, S.; Nowogrodzki, M.; Magdyca, M.; Potopnyk, M. Carbobicyclic sugar mimics. 
Carbohydr. Chem. 2012, 37, 303-325. 
45. Soengas, R. G.; Otero, J. M.; Estevez, A. M.; Praster, A. P.; Cachatra, V.; Estevez, J. C.; Estevez, 
R. J. An overview of key routes for the transformation of sugars into carbasugars and related 
compounds. Carbohydr. Chem, 2012, 38, 263-302. 
46. Lahiri, R.; Ansari, A. A.; Vankar, Y. D. Recent developments in design and synthesis of bicyclic 
azasugars, carbasugars and related molecules as glycosidase inhibitors. Chem. Soc. Rev. 2013, 42, 
5102-5118. 
 39
                                                                                                                                               
47. Bessieres, M.; Chevrier, F.; Roy, V.; Agrofoglio, L. Recent progress for the synthesis of selected 
carbocyclic nucleosides. Future Med. Chem. 2015, 7, 1809-1828. 
48. Chemical Synthesis of Nucleoside Analogues. P. Merino, ed. Wiley, 2013. 
49. Adinolfi, M.; Corsaro, M. M.; De Castro, C.; Evidente, A.; Lanzetta, R.; Molinaro, A.; Parrilli, 
M. Caryose: a carbocyclic monosaccharide from Pseudomonas caryophylli. Carbohydr. Res. 
1996, 284, 111-118. 
50. Adinolfi, M.; Corsaro, M. M.; DeCastro, C.; Evidente, A.; Lanzetta, R.; Lavermicocca, M.; 
Parrilli, M. Analysis of the polysaccharide components of the lipopolysaccharide fraction of 
Pseudomonas caryophylli. Carbohydr. Res. 1996, 284, 119-133. 
51. Adinolfi, M.; Barone, G.; Iadonisi, A.; Mangoni, L.; Manna, R. Synthesis of caryose, the 
carbocyclic monosaccharide component of the lipopolysaccharide from Pseudomonas 
caryophylli. Tetrahedron 1997, 53, 11767-11780. 
52. Brock, T. D.; Brock, K. M.; Belly, R. T.; Weiss, R. L. Sulfolobus: a new genus of sulphur-
oxidizing bacteria living at low pH and high temperature. Archiv fur Mikrobiol. 1972, 84, 54–68. 
53. De Rosa, M.; De Rosa, S.; Gambacorta, A.; Minale, L.; Bullock, J. D. Chemical structure of the 
ether lipids of thermophilic acidophilic bacteria of the Caldariella group. Phytochemistry 1977, 
16, 1961-1965. 
54. De Rosa, M.; De Rosa, S.; Gambacorta, A.; Bullock, J. D. Structure of calditol, a new branched-
chain nonitol, and of the derived tetraether lipids in thermoacidophile archaebacteria of the 
Caldariella group. Phytochemistry 1980, 19, 249-254. 
55. Bode, M. L.; Buddoo, S. A.; Minnaar, S. H.; du Plessis, C. A. Extraction, isolation and NMR 
data of the tetraether lipid calditol glycerocaldarchaeol (GDNT) from Sulfolobus metallicus 
harvested from a bioleaching reactor. Chem.Phys.Lipids 2008, 154, 94-104. 
56. Untersteller, E.; Fritz, B.; Bliériot, Y.; Sinaÿ, P. The structure of calditol isolated from the 
thermoacidophilic archaebacterium Sulfolobus acidocaldarius. Compt. Rend. Acad. Sci (IIC-
Chem.) 1999, 429-433. 
57. Bleriot, Y.; Untersteller, E.; Fritz;, B.; Sinaÿ, P. Total synthesis of calditol: structural 
clarification of this typical component of archaea order Sulfolobales. Chem. Eur. J. 2002, 8, 240-
246. 
58. Miller, T. W.; Arison, B. H.; Albers-Schonberg, G. Isolation of a cyclitol antibiotic: 2,3,4,5-
tetrahydroxycyclohexanemethanol. Biotechnol. Bioeng. 1973, 15, 1075-1080. 
59. Marco-Contelles, J.; Molina, M. T.; Anjum, S. Naturally occurring cyclohexane epoxides: 
sources, biological activities, and synthesis. Chem. Rev. 2004, 104, 2857-2899. 
60. Thebtaranonth, Ch.; Thebtaranonth, Y. Naturally occurring cyclohexene oxides Acc. Chem. Res. 
1986, 19, 84-90. 
61. Marco-Contelles, J. Cyclohexane Epoxides − Chemistry and Biochemistry of (+)-Cyclophellitol. 
Eur. J. Org. Chem. 2001, 1607-1618. 
62. Kobayashi, Y. Glycoscience, Chemistry and Chemical Biology; Fraser-Reid, B., Tatsuta, K., 
Thiem, J., Eds.; Springer-Verlag: Berlin, 2001; Chapter 10.3, Vol. III. 
63. Tatsuta, K. Total synthesis and chemical design of useful glycosidase inhibitors. Pure Appl. 
Chem. 1996, 68, 1341-1346. 
64. Ogawa, S.; Kanto, M. Synthesis of bio-active compounds from cyclitol derivatives provided by 
bioconversion of myo-inositol. Curr. Trends Med. Chem. 2008, 5, 1-13. 
65. Fraser-Reid, B.; Lopez, J. C. Unsaturated sugars: a rich platform for methodological and 
synthetic studies. Curr. Org. Chem. 2009, 13, 532-553. 
66. Nobuji, Y.; Noriko, C.; Takashi, M.; Shigeru, U.; Kenzon, A.; Michaki, I. Jpn. Kokai Tokkyo 
Koho, JP, 06306000, 1994.  
67. Isogai, A.; Sakuda, S.; Nakayama, J.; Watanabe, S.; Suzuki, A. Isolation and structural 
elucidation of a new cyclitol derivative, streptol, as a plant growth regulator. Agricultural Biol. 
Chem. 1987, 51, 2277-2279. 
68. Sedmera, P.; Halada, P.; Pospisil, S. New carbasugars from Streptomyces lincolnensis. Magn. 
Res. Chem. 2009, 47, 519-522.. 
69. Yamada, T.; Iritani, M.; Ohishi, H.; Tanaka, K.; Minoura, K.; Doi, M.; Numata, A. Pericosines, 
antitumor metabolites from the sea hare-derived fungus Periconia byssoides. Structures and 
biological activities. Org. Biomol. Chem. 2007. 5, 3979-3986. 
70. For a review, see: Usami, V. Synthesis of marine-derived carbasugar pericosines. Studies Nat. 
Prod. Chem. 2014, 41, 287-319. 
71. Bayon, P.; Figueredo, M. The Gabosine and Anhydrogabosine Family of Secondary Metabolites. 
Chem. Rev. 2013, 113, 4680-4707. 
 40
                                                                                                                                               
72. Mac, D. H.; Chandrasekhar, S.; Gree, R. Total Synthesis of Gabosines. Eur. J. Org. Chem. 2012, 
5881-5895. 
73. Das, M.; Manna, K. Bioactive Cyclohexenones: A Mini Review. Curr. Bioactiv. Comp. 2015, 
11, 239-248. 
74. Chimura, H.; Nakamura, T.; Takita, T.;  Takeuchi, H.; Umezawa, K.; Kato, S.; Saito, T.; 
Tomisawa, Y.; Iitaka,Y. The structure of a glyoxalase I inhibitor and its chemical reactivity with 
SH-compounds. J. Antibiot. 1975, 28, 743-748. 
75.  Kameda, Y.; Horii, S. The unsaturated cyclitol part of the new antibiotics, the validamycins. J. 
Chem. Soc., Chem. Commun. 1972, 746-747. 
76. Kameda, Y.; Horii, S. Microbial transformation of validamycins. J. Antibiot. 1975, 28, 298-306. 
77. Kameda, Y.; Asano, N.; Teranishi, M.; Matsui, K. New cyclitols, degradation of validamycin A 
by Flavobacterium saccharophilum. J. Antibiot. 1980, 33, 1573-1574.. 
78. Kameda, Y.; Asano, N.; Teranishi, M.; Yoshikawa, M.; Matsui, K. Cefmetazole in the treatment 
of bacterial infections in the newborn. J. Antibiot. 1981, 34, 1237-1246. 
79. Asano, N.; Takeuchi, M.; Ninomiya, K.; Kameda, Y.; Matsui, K. Microbial degradation of 
validamycin A by Flavobacterium saccharophilum. Enzymatic cleavage of C-N linkage in 
validoxylamine A. J. Antibiot. 1984, 37, 859-867. 
80. Ogawa, S.; Miyamoto, Y.; Nakajima, A. Cleavage of the Imino Bonds of Validoxylamine A 
Derivatives with N-Bromosuccinimide. Chem. Lett. 1989, 725-728. 
81. Ogawa, S.; Nakajima, A.; Miyamoto, Y. Cleavage of validoxylamine A derivatives with N-
bromosuccinimide: preparation of blocked synthons useful for the construction of carba-
oligosaccharides composed of imino linkages. J. Chem. Soc. Perkin Trans. 1 1991, 3287-3290. 
82.  Xu, H.; Yang, J.; Bai, L.; Deng, Z.; Mahmud, T. Genetically engineered production of 1,1'-bis-
valienamine and validienamycin in Streptomyces hygroscopicus and their conversion to 
valienamine. Applied Microbiol. 2009, 81, 895-902. 
83. Xue, Y.-P.; Zheng, Y.-G.; Shen, Y.-Ch. Enhanced production of valienamine by 
Stenotrophomonas maltrophilia with fed-batch culture in a stirred tank bioreactor. Process 
Biochem. 2007, 42, 1033-1038. 
84. Wang, Y.-S.; Zheng, Y.-G.; Shen, Y.-C, J. Isolation and identification of a novel valienamine-
producing bacterium. Applied Microbiol. 2007, 102, 838-844. 
85. Horii, S.; Iwasa, T.; Kameda, Y. Validamycins, new antibiotics. V. Degradation studies. J. 
Antibiot. 1971, 24, 57-58. 
86. Horii, S.; Iwasa, T.; Kameda, Y. Studies on validamycins, new antibiotics. VI. Validamine, 
hydroxyvalidamine and validatol, new cyclictols. J. Antibiot. 1971, 24, 59-63. 
87. Kameda, Y.; Asano, N.; Yoshikawa, M.; Takeuchi, M.; Yamaguchi, T.; Matsui, K.; Horii, S.; 
Fukase, H. Valiolamine, a new α-glucosidase inhibiting aminocyclitol produced by Streptomyces 
hygroscopicus. J. Antibiot 1984, 37, 1301-1307. 
88. Mahmud T., The C7N aminocyclitol family of natural products.  Nat. Prod. Reports 2003, 20, 
137-166. 
89. Suami, T. Synthesis of biologically active pseudo-oligosaccharides. Carbohydrates. Ogura, H.; 
Hasegawa, A.; Suami, T. eds., Verlag (VCH), 1992, p. 136-173. 
90. Iwasa, T.; Yamamoto, H.; Shibata, M. J. Studies on validamycins, new antibiotics. I. 
Streptomyces hygroscopicus var. limoneus., validamycin-producing organism. J. Antibiot. 1970, 
23, 595-602. 
91. Iwasa, T.; Higashide, E.; Yamamoto, H.; Shibata, M. J. Studies on validamycins, new antibiotics. 
II. Production and biological properties of validamycins A and B. J. Antibiot. 1971, 24, 107-113. 
92. Horii, S.; Kameda, Y.; Kawahara, K. Validamycins, new antibiotics. 8. Isolation and 
characterization of validamycins C,D,E and F. J. Antibiot. 1972, 25, 48-53. 
93. Kameda, Y.; Asano, N.; Matsui, K.; Horii, H.; Fukase, H. Structures of minor components of the 
Validamycin complex. J. Antibiot. 1989, 41, 1488-1492. 
94. Kameda, Y.; Asano, N.; Yamaguchi, T.; Matsui, K.; Horii, H.; Fukase, H. Validamycin G and 
validoxylamine G, new members of the validamycins. J. Antibiot. 1986, 39, 1491-1494. 
95. Asano, N.; Kameda, Y.; Matsui, K.; Horii, H.; Fukase, H. Validamycin H, a new pseudo-
tetrasaccharide antibiotic. J. Antibiot. 1990, 43, 1039-1041. 
96. Schmidt, D. D.; Frommer, W.; Junge, B.; Muller, L.; Wingender, W.; Truscheit, E.; Schafer, D. 
α-glucosidase inhibitors. New complex oligosaccharides of microbial origin Naturwissenschaften 
1977, 64, 535-536. 
97. Junge, B.; Heiken, R.-R.; Kurz, J.; Muller, L.; Schmidt, D. D.; Wunsche, C. Untersuchungen zur 
struktur des α-d-glucosidaseinhibitors acarbose. Carbohydr. Res. 1984, 128, 235-268. 
 41
                                                                                                                                               
98. Masharani, U.; German, M. S. Pancreatic Hormones and Diabetes Mellitus. Greenspan's basic & clinical 
endocrinology (9th ed.). Gardner, D. G.; Shoback, D. eds. McGraw-Hill Medical, 2011, Chapter 17 
99. Buse, J. B.; Polonsky, K. S.; Burant, Ch. F. Type 2 Diabetes Mellitus. Melmed, S.; Polonsky, K. S.; Larsen, 
P. R.; Kronenberg, H. M. eds. Williams textbook of endocrinology (12th ed.) Elsevier, 2012, Section 7, 
Chapter 31. 
100. Kadziola, A.; Abe, J.; Svensson, B.; Haser, R. Crystal and molecular structure of barley alpha-
amylase. J. Mol. Biol. 1994, 239, 104–121. 
101. Machius, M.; Wiegand, G.; Huber, R. Crystal structure of calcium-depleted Bacillus 
licheniformis alpha-amylase at 2.2 A resolution. J. Mol. Biol. 1995, 246, 545–559. 
102. Hemker, M.; Stratmann, A.; Goeke, K.; Schroder, W.; Lenz, J.; Piepersberg, W.; Pape, H. 
Identification, Cloning, Expression, and Characterization of the Extracellular Acarbose-
Modifying Glycosyltransferase, AcbD, from Actinoplanes sp. Strain SE50.  J. Bacteriol. 2001, 
183, 4484-4492. 
103. Truscheit, E.; Frommer, W.; Junge, B.; Muller, L.; Schmidt, D.; Wingeder, W. Chemistry and 
Biochemistry of Microbial α-Glucosidase Inhibitors. Angew. Chem., Int. Ed. Engl. 1981, 20, 
744-761. 
104. Wehmeier, U. F.; Piepersberg, W. Biotechnology and molecular biology of the α-glucosidase 
inhibitor acarbose Appl. Microbiol. Biotechnol. 2004, 63, 613-625. 
105. Wehmeier, U. F. The Biosynthesis and Metabolism of Acarbose in Actinoplanes species SE 
50/110. Progress Report. Biocatal. Biotransf. 2003, 21, 279-284. 
106. Laube, H. Acarbose.  An Update of Its Therapeutic Use in Diabetes Treatment Clin. Drug. 
Invest. 2002, 22, 141-156. 
107.  Scheen, A. J. Clinical efficacy of acarbose in diabetes mellitus: A critical review of controlled 
trials. Diabetes Metabol. 1998, 24, 311-320. 
108.  Breuer, H.-W. M. Review of acarbose therapeutic strategies in the long-term treatment and in the 
prevention of type 2 diabetes. Int. J. Clin. Pharmacol. Therapeut. 2003, 41, 421-440. 
109. Ogawa, S.; Kanto, M.; Suzuki, Y. Development and medical application of unsaturated 
carbaglycosylamine glycosidase inhibitors. Mini-Rev. Med. Chem. 2007, 7, 679-691. 
110. Bedekar, A.; Shah, K.; Koffas, M. Natural products for type II diabetes treatment. Adv. Appl. 
Microbiol. 2010, 71, 21-73. 
111. Rios, J. L.; Francini, F.; Schinella, G. R. Natural Products for the Treatment of Type 2 Diabetes 
Mellitus. Planta Medica 2015, 81, 975-994. 
112. Harvey, A. L. Plant natural products in anti-diabetic drug discovery. Curr. Org. Chem. 2010, 14, 
1670-1677. 
113. Moorthy, N. S. H. N.; Ramos, M. J.; Fernandes, P. A. Studies on α-glucosidase inhibitors 
development: magic molecules for the treatment of carbohydrate mediated diseases. Mini-Rev. 
Med. Chem. 2012, 12, 713-720. 
114. Ghani, U. Re-exploring promising α-glucosidase inhibitors for potential development into oral 
anti-diabetic drugs: Finding needle in the haystack. Eur. J. Med. Chem. 2015, 103, 133-162. 
115. Fukuhara, K.-i.; Murai, H.; Murao, S. Amylostatins, other amylase inhibitors produced by 
Streptomyces diastaticus subsp. Amylostaticus No 2476. Agric. Biol. Chem. 1982, 46, 2021-
2030. 
116. Fukuhara, K.-i.; Murai, H.; Murao, S. Isolation and Structure-activity Relationship of Some 
Amylostatins (F-1b Fraction) Produced by Streptomyces diastaticus subsp. Amylostaticus No 
9410. Agric. Biol. Chem. 1982, 46, 1941-1945. 
117. Namiki, S.; Kangouri, K.; Nagate, T.; Hara, H.; Sugita, K.; Omura, S. Studies on the α-glucoside 
hydrolase inhibitor, Adiposin I. Isolation and physicochemical properties. J. Antibiot. 1982, 35, 
1234-1236. 
118. Namiki, S.; Kangouri, K.; Nagate, T.; Hara, H.; Sugita, K.; Omura, S. Studies on the α.-
glucoside hydrolase inhibitor, adiposin. II. Taxonomic studies on the producing microorganism. 
J. Antibiot. 1982, 35, 1156-1159. 
119. Kangouri, K.; Namiki, S.; Nagate, T.; Hara, H.; Sugita, K.; Omura, S. Studies on the α-glucoside 
hydrolase inhibitor, adiposin. III. α-Glucoside hydrolase inhibitory activity and antibacterial 
activity in vitro. J. Antibiot. 1982, 35, 1160-1166. 
120. Namiki, S.; Kangouri, K.; Nagate, T.; Hara, H.; Sugita, K.; Noda, K.; Tarumoto, Y.; Omura, S. 
Studies on the α-glucoside hydrolase inhibitor, adiposin. IV. Effect of adiposin on intestinal 
digestion of carbohydrates in experimental animals. J. Antibiot. 1982, 35, 1167-1173. 
121. Ogawa, S.; Iwasawa, Y.; Toyokuni, T.; Suami, T. Synthesis of adiposin-1, α-glucoside hydrolase 
inhibitor. Chem. Lett. 1983, 337-340. 
 42
                                                                                                                                               
122. Ogawa, S.; Iwasawa, Y.; Toyokuni, T.; Suami, T. Synthesis of pseudooligosaccharidic 
glycosidase inhibitors. Part 1. Synthesis of adiposin-1 and related compounds. Carbohydr. Res. 
1985, 141, 29-40. 
123. Ogawa, S.; Shibata, Y. Total synthesis of acarbose and adiposin-2. J. Chem. Soc. Chem.. Comm. 
1988, 605-606. 
124. Shibata, Y.; Ogawa, S. Synthesis of pseudo-oligosaccharide glycosidase inhibitors. Part VII. 
Total synthesis of acarbose and adiposin-2. Carbohydr. Res, 1989, 189, 309-322.  
125. Itoh, J.; Omoto, S.; Shomura, T.; Ogino, H.; Iwamatsu, K.; Inouye, S.; Hidaka, H. Oligostatins, 
new antibiotics with amylase inhibitory activity. I. Production, isolation and characterization. J. 
Antibiot. 1981, 34, 1424-1428. 
126. Omoto, S.; Itoh, J.; Ogino, H.; Iwamatsu, K.; Nishizawa, N.; Inouye, S. Oligostatins, new 
antibiotics with amylase inhibitory activity. II. Structures of oligostatins C, D and E. J. Antibiot. 
1981, 34, 1429-1433. 
127. Ogawa, S.; Iwasawa, Y.; Toyokuni, T.; Suami, T. Synthesis of a common structural unit of the 
antibiotic Oligostatins. Chem. Lett. 1982, 1729-1732. 
128. Ogawa, S.; Iwasawa, Y.; Toyokuni, T.; Suami, T. Synthesis of pseudo-oligosaccharide 
glycosidase inhibitors. Part IV. Synthesis of a core structure of the antibiotic oligostatin. 
Carbohydr. Res. 1985, 144, 155-162. 
129. Shibata, Y.; Kosuge, Y.; Ogawa, S. Synthesis of pseudooligosaccharide glycosidase inhibitors. 
VII. Synthesis and biological activities of methyl oligobiosaminide and some deoxy isomers 
thereof. Carbohydr. Res. 1990, 199, 37-54. 
130. Watanabe, K.; Furumai, T.; Sudoh, M.; Yokose, K.; Muruyama, H. B. New α.-amylase inhibitor, 
trestatins. IV. Taxonomy of the producing strains and fermentation of trestatin A. J. Antibiot. 
1984, 37, 479-486. 
131. Yokose, K.; Ogawa, K.; Sano, T.; Watanabe, K.; Maruyama, H.-B.; Suhara, Y. New α-amylase 
inhibitor, trestatins. I. Isolation, characterization and biological activities of trestatins A, B and 
C.  J. Antibiot. 1983, 36, 1157-1165. 
132. Vértesy, L.; Fehlhaber, H.-W.; Schulz, A. The trehalase inhibitor salbostatin, a novel metabolite 
from Streptomyces albus, ATCC21838. Angew. Chem., Int. Ed. Engl. 1994, 33, 1844-1846. 
133. Yamagishi, T.; Uchida, Ch.; Ogawa, S. Total synthesis of the trehalase inhibitor salbostatin. 
Chem. Eur. J. 1996, 1, 634-636. 
134. Yamagishi, T.; Uchida, Ch.; Ogawa, S. Total synthesis of trehalase inhibitor salbostatin. Biorg. 
Med. Chem. Lett. 1995, 5, 487-490. 
135. Kawamura, N.; Kinoshita, N.; Sawa, R.; Takahashi, Y.; Sawa, T.; Naganawa, H.; Hamada, M.; 
Takeuchi, T. Pyralomicins, novel antibiotics from Microtetraspora spiralis. I. Taxonomy and 
production. J. Antibiot. 1996, 49, 706-709. 
136. Kawamura, N.; Sawa, R.; Takahashi, Y.; Issiki, K.; Sawa, T.; Kinoshita, N.; Naganawa, H.; 
Hamada, M.; Takeuchi, T. Pyralomicins, new antibiotics from Actinomadura spiralis. J. Antibiot. 
1995, 48, 435-437. 
137. Kawamura, N.; Sawa, R.; Takahashi, Y.; Issiki, K.; Sawa, T.; Kinoshita, N.; Naganawa, H.; 
Takeuchi, T. Pyralomicins, novel antibiotics from Microtetraspora spiralis. II. Structure 
determination. J. Antibiot. 1996, 49, 651-656. 
138. Kelly, T. R.; Moiseyeva, R. L. Total Synthesis of the Pyralomicinones. J. Org. Chem. 1998, 63, 
3147-3150. 
139. Tatsuta, K.; Takahashi, M.; Tanaka, N. The first total synthesis of pyralomicin 2c. Tetrahedron 
Lett. 1999, 40, 1929-1932. 
140. Tatsuta, K.; Takahashi, M.; Tanaka, N. The first total synthesis of pyralomicin 1c. J. Antibiot. 
2000, 53, 88-91. 
141. Jenkins, G. N.; Turner, N, The biosynthesis of carbocyclic nucleosides. Chem. Soc. Rev. 1995, 
24, 169-176. 
142. Parry, R. J., Investigations of the biosynthesis of aristeromycin. Environ. Sci. Research 1992, 44, 
89-104. 
143. Hill, J. M.; Jenkins, G. N.; Rush, C. P.; Turner, N. J.; Willetts, A. J.; Buss, A. D.; Dawson, M. J.; 
Rudd, B. A. M., Revised pathway for the biosynthesis of aristeromycin and neplanocin A from 
D-glucose in Streptomyces citricolor. J .Am.Chem.Soc. 1995, 117, 5391-5392. 
144. Parry, R. J.; Jian, Y., The biosynthesis of aristeromycin. Conversion of neplanocin A to 
aristeromycin by a novel enzymic reduction. Tetrahedron Lett. 1994, 35, 9665-9668. 
145. Review: Gambacorta, A.; Gliozzi, A.; De Rosa, M. World, J. Archeal lipids and their 
biotechnological applications. Microbiol. Biotechnol. 1995, 11, 115-131. 
 43
                                                                                                                                               
146. Gambacorta, A; Caracciolo, G.; Trabasso, D.; Izzo, I.; Spinella, A.; Sodano, G. Biosynthesis of 
calditol, the cyclopentanoid containing moiety of the membrane lipids of the archaeon Sulfolobus 
solfataricus. Tetrahedron Lett. 2002, 43, 451-453. 
147. Yamauchi, N.; Ueoka, H.; Kamada, N.; Murae, T. Resemblance of carbocycle formation from 
carbohydrates between archaea and eucarya/eubacteria. Biosynthesis of calditol, the 
characteristic lipid-content molecule in Sulfolobus acidocaldarius. Bull. Chem. Soc. Jpn. 2004, 
77, 771-778. 
148. Yamauchi, N.; Kamada, N.; Ueoka, H.,  The possibility of involvement of "cyclase" enzyme of 
the calditol carbocycle with broad substrate specificity in Sulfolobus acidcaldarius, a typical 
thermophilic archaea. Chem. Lett. 2006, 35, 1230-1231. 
149. For the biosynthesis of the lipid moiety, see: Nicolau, B.; Trincone, A.; Esposito, E.; Vaccaro, 
M. R.; Gambacorta, A.; De Rosa, M., Calditol tetraether lipids of the archaebacterium Sulfolobus 
solfataricus. Biosynthetic studies. Biochem. J. 1990, 266, 785-791. 
150. Voet, D.; Voet, J. G. in Biochemistry, 3nd.. Edition, Wiley, 2004. Chapter 21. 
151. Berg, J. M.; Tymoczko, J. L.; Stryer, L. Biochemistry, 5th. Edition. W.H. Freeman, 2002, 
Chapter 20.  
152. Widlanski, T.; Bender, S. L.; Knowles, J. R. Dehydroquinate synthase: a sheep in wolf's 
clothing?. J. Am. Chem. Soc. 1989, 111, 2299-2300. 
153. Stratmann, A.; Mahmud, T.; Lee, S.; Distler, J.; Floss, H. G.; Piepersberg, W. The AcbC protein 
from Actinoplanes species is a C7-cyclitol synthase related to 3-dehydroquinate synthases and is 
involved in the biosynthesis of the α-glucosidase inhibitor acarbose.  J. Biol. Chem. 1999, 274, 
10889-10896. 
154. Asamizu, S.; Xie, P.; Brumsted, C. J.; Flatt, P. M.; Mahmud, T. Evolutionary Divergence of  
Sedoheptulose 7-Phosphate Cyclases Leads to Several Distinct Cyclic Products, J. Am. Chem. 
Soc. 2012, 134, 12219−12229. 
155. Kean, K. M.; Codding, S. J.; Asamizu, S.; Mahmud, T.; Karplus, P. A. Structure of a 
sedoheptulose 7-phosphate cyclase: ValA from Streptomyces hygroscopicus. Biochem. 2014, 53, 
4250-4260.  
156. Carpenter, E. P.; Hawkins, A. R.; Frost J. W.; Brown, K. A. Structure of dehydroquinate 
synthase reveals an active site capable of multistep catalysis. Nature 1998, 394, 299-302. 
157. Herrmann, K. M., The Shikimate Pathway: Early Steps in the Biosynthesis of Aromatic 
Compounds. Plant Cell 1995, 7, 907-919. 
158. Höfs, R.; Schoppe, S.; Thiericke, R.; Zeeck, Biosynthesis of Gabosines A, B, and C, Carba 
Sugars from Streptomyces cellulosae. Eur. J. Org. Chem. 2000, 1883-1887. 
159. Liu, S.-Y.; Rosazza, J. P. N. Enzymatic Conversion of Glucose to UDP-4-Keto-6-Deoxyglucose 
in Streptomyces spp. Appl. Environ. Microbiol. 1998, 64, 103972-103976. 
160. Thibodeaux, Ch. J., Melangon, Ch. E.; Liu, H. Unusual sugar biosynthesis and natural product 
glycodiversification. Nature 2007, 446, 1008-1016. 
161. Fresneda, M. A.; Alibés, R.; Font, J.; Bayón, P.; Figueredo, M. How a diversity.oriented 
approach has inspired a new hypothesis for the gabosine byosynthetic pathway. A new synthesis 
of (+)-gabosine C. Org. Biomol. Chem. 2013, 11, 6562-6568. 
162. Alibés, R.; Bayón, P.; de March, P.; Figueredo, M.; Font, J.; Marjanet, G. Enantioselective 
Synthesis and Absolute Configuration Assignment of Gabosine O. Stnthesis of (+)- and (-)-
Gabosine N and (+)-and (-)-Epigabosines N and O. Org. Lett. 2006, 8, 1617-1620. 
163. Review: Singh, S.; Anand, A.; Srivastava, P. K. Regulation and properties of glucose- 6-
phosphate dehydrogenase: a review. Int. J. Plant Physiol. Biochem. 2012, 4, 1-19 and references 
therein. 
164. For a short review, see: Hofer, H. W.; Bauer, H. P. 6-Phosphogluconolactonase. Cell Biochem. 
Funct. 1987, 5, 97-99. 
165. Rippa, M.; Hanau, S.; Cervellati, C.; Dallocchio, F. 6-Phosphogluconate dehydrogenase: 
structural symmetry and functional asymmetry. Protein Pept. Lett, 2000, 7, 341-348. 
166. Williamson, W. T.; Wood, W. A. D-Ribulose-5-phosphate 3-epimerase. Methods Enzymol. 1966, 
9, 605-608. 
167. Wood, T. Assay for D-ribose-5-phosphate ketol isomerase and D-ribulose-5-phosphate 3-
epimerase, Methods Enzymol. 1975, 41, 63-66. 
168. Kochetov, G. A.; Solovjeva, O. N. Structure and functioning mechanism of transketolase. 
Biochim. Biophys. Acta, 2014, 1844, 1608-1618. 
169. Ranoux, A.; Hanefeld, U. Improving Transketolase. Topics Catalys. 2013, 56, 750-764. 
 44
                                                                                                                                               
170. For a review considering the use of transketolases in various organic synthesis, see: (c)  
Wohlgemuth, R.; Smith, M. E. B.; Dalby, P. A.; Woodley, J. M. Transketolases. Encyclopedia of 
Industrial Biotechnology. Flickinger, M. C. ed., Wiley, 2010, Vol. 7, p. 4746-4752. 
171. Dong, H.; Mahmud, T.; Tornus, I.; Lee, S.; G. Floss, H.G. Biosynthesis of the Validamycins: 
Identification of Intermediates in the Biosynthesis of Validamycin A by Streptomyces 
hygroscopicus var. limoneus. J. Am. Chem. Soc. 2001, 123, 2733-2742. 
172. Lee, S.-H.; Choe, H.; Bae, K. S.; Park, D.-S.; Nasir, A.; Kim, K. M. Complete genome of 
Streptomyces hygroscopicus subsp. limoneus KCTC 1717 (=KCCM 11405), a soil bacterium 
producing validamycin and diverse secondary metabolites. J. Biotech. 2016, 219, 1-2. 
173. Lee, S.; Egelkrout, E. Biosynthetic studies on the α-glucosidase inhibitor acarbose in 
Actinoplanes sp.: glutamate is the primary source of the nitrogen in acarbose. J. Antibiot. 1998, 
51, 225-227. 
174. Patterson, M. K., Jr.; Orr, G. R. Asparagine biosynthesis by the Novikoff hepatoma. Isolation, 
purification, property, and mechanism studies of the enzyme system. J. Biol. Chem. 1968, 243, 
376–380. 
175. Tesson, A. R.; Soper, T. S.; Ciustea, M.; Richards, N. G. Revisiting the steady state kinetic 
mechanism of glutamine-dependent asparagine synthetase from Escherichia coli. Arch. Biochem. 
Biophys. 2003, 413, 23–31. 
176. Mahmud, T.; Lee, S.; Floss, H. G. The biosynthesis of acarbose and validamycin. Chem. Rec. 
2001, 1, 300-310. 
177. Arakawa, K.; Bowers, S. G.; Michels, B.; Trin, V.; Mahmud, T. Biosynthetic studies on the -
glucosidase inhibitor of acarbose: the chemicals synthesis of isotopically labeled 2-epi-5-epi 
valiolone analogs. Carbohydr. Res. 2003, 338, 2075- 2082. 
178. Mahmud, T.; Tornus, I.; Egelkrout, E.; Wolf, E.; Uy, C.; Floss, H. G.; Lee, S. Biosynthetic 
studies on the -glucosidase inhibitor acarbose in Actinoplates sp.: 2-epi-5-epi-valiolones is the 
direct precursor of the valienamine moiety. J. Am. Chem. Soc. 1999, 121, 6973-6983. 
179. See The ACS style guide: effective communication of scientific diphosphates information, 3rd ed. 
Coghill, A. M.; Garson, L. R. ed. American Chemical Society. Washington, D.C. 2006, p. 244. 
180. Selected review: Cui, Q.; Shin, W. S.; Luo, Y.; Tian, J.; Cui, H.; Yin, D. Thymidylate kinase: an 
old topic brings new perspectives Curr. Med. Chem. 2013, 20, 1286-1305. 
181. Lee, S.; Sauerbrei, B.; Niggemann, J.; Egelkrout, E. Biosynthetic studies on the α-glucosidase 
inhibitor acarbose in Actinoplanes sp.: source of the maltose unit. J. Antibiot. 1997, 50, 954-960. 
182. Bowers, S. G.; Mahmud, T.; Floss, H. G. Biosynthetic studies on the alpha-glucosidase inhibitor 
acarbose: the chemical synthesis of dTDP-4-amino-4,6-dideoxy-alpha-glucose. Carbohydr. Res. 
2002, 337, 297-304. 
183. Wehmeier, U. F.; Piepersberg, W. Enzymology of Aminoglycoside Biosynthesis-Deduction from 
Gene Cluster. Methods in Enzymology. Vol 459. Complex Enzymes in Microbial Natural 
Products Biosynthesis. Part B.: Polyketides, Aminocoumarins and Carbohydrates. Howood, D. A. 
ed.. Elsevier, 2009. Chapter 19, p. 479. 
184. Lodish, H.; Berk, A.; Kaiser, Ch.; Krieger, M.; Bretscher, A.; Ploegh, H.; Amon, A.; Mathew, S. 
Genes, Genomics and Chromosomes. Molecular Cell Biology. 7 ed., Freeman, 2013. p 227-230. 
185. Gangman, Y.; Sze, S.-H.; Thon, M. Identifying clusters in functionally related genes in genomes. 
Bioinformatics 2007, 23, 1053–1060. 
186. Overbeek, R.; Fonstein, M.; D'Souza, M.; Pusch, G.; Maitsev, D. The Use of Gene Clusters to 
Infer Functional Coupling. Proceed. Nat. Acad. Sci. USA 1999, 96, 2896–2901. 
187. J. Yang; H. Xu; Y. Zhang; L. Bai; Z. Deng; T. Mahmud. Nucleotidylation of Unsaturated 
Carbasugars in Validamycin Biosynthesis. Org. Biomol. Chem. 2011, 9, 438-439. 
188. Zhang, Ch.-S.; Podeschwa, M.; Altenbach, H.-J.; Piepersberg, W.; Wehmeier, U. F. 
Identification of a 1-epi-vañienol 7-kinase activity in the producer of acarbose, Actinoplates sp. 
SE50/110. FEBS Lett. 2003, 540, 53-57. 
189. Zhang, Ch.-S.; Stratmann, A.; Block, O.; Bruckner, R.; Podeschwa, M.; Altenbach, H.-J.; 
Wehmeier, U. F.; Piepersberg, W. Biosynthesis of the C7-ciclytol moiety of acarbose in 
Actinoplates species SE50/110: 7-O-phosphorylation of the initial cyclitol precursors lead to 
proposeed a new biosynthetic pathway.  J. Biol. Chem. 2002, 277, 22853-22862. 
190. Stratmann, A.; Mahmud, T.; Lee, S.; Distler, J.; Floss, H. G.; Piepersberg, W. The AcbC protein 
from Actinoplanes species is a C7-cyclitol synthase related to 3-dehydroquinate synthases and is 
involved in the biosynthesis of the α-glucosidase inhibitor acarbose. J. Biol. Chem. 1999, 274, 
10889-10896. 
 45
                                                                                                                                               
191. Wendler, S.; Ortseifen, V.; Persicke, M.; Klein, A.; Neshat, A.; Niehaus, K.; Schneiker-Bekel, 
S.; Walter, F.; Wehmeier, Udo F.; Kalinowski, J.; Puehler, A. Carbon source-dependent 
biosynthesis of acarviose metabolites in Actinoplanes sp. SE50/110. J. Biotech. 2014, 191, 113-
120. 
192. See D. E. Metzler. Biochemistry. The Chemical reactions of Living Cells. 2nd Edition. Elsevier, 
2003. Vol. 1, p. 545. 
193. Flatt, P. M.; Wu, X.; Perry, S.; Mahmud, T. Genetic Insights into Pyralomicin Biosynthesis in 
Nonomuraeae spiralis IMC A-0156. J. Nat. Prod. 2013, 76, 939-946. 
194. Schwarzer, D.; Finking, R., Mohamed A.; Marahiel, M. A. Nonribosomal peptides: from genes 
to products. Nat. Prod. Rep. 2003, 20, 275-287 
195. Marahiel, M. A.; Stachelhaus, T.;  Mootz , H. D. Modular Peptide Synthetases Involved in 
Nonribosomal Peptide Synthesis, Chem. Rev. 1997, 97, 2651–2674. 
196. Khosla, C.; Gokhale, R. S.; Jacobsen, J. R.; Cane, D. E. Tolerance and Specificity of Polyketide 
Synthases. Ann. Rev. Biochem. 1999, 68, 219–253. 
197. Jenke-Kodama, H.; Sandmann, A.; Müller, R.; Dittmann, E. Evolutionary Implications of 
Bacterial Polyketide Synthases. Mol. Biol.& Evol. 2005, 22, 2027–2039. 
198. Lodish, H.; Zipursky, L.; Matsudaira, P. B., David, D.; Darnel, J. Molecular Definition of a Gene 
Molecular Cell Biology. Freeman, 2000, Chapter 9. 
199. Williams, G. J. Engineering polyketide synthases and nonribosomal peptide synthetases. Proc. 
Natl. Acad. Sci. USA 2003, 100, 3010-3012. 
200. Hutchinson, C. R. Polyketide and non-ribosomal peptide synthases: Falling together by coming 
apart. Nat. Prod. Reports 2007, 24, 1073-1090. 
201. Horsman, M.E.;  Taylor P. A.; Hari, T.P.A.; Boddy, Ch.N.  Polyketide synthase and non-
ribosomal peptide synthetase thioesterase selectivity: logic gate or a victim of fate?. Nat. Prod. 
Rep. 2016, 33, 183-202. 
202. Smith, D. M. R.; Grüschow, S.; Goss, R. J. M. Scope and potential of halogenases in 
biosynthetic applications. Curr. Op. Chem. Biol. 2013, 17, 276-283. 
203. Lam, K. C.; Ibrahim, R. K.; Behdad, B.; Dayanandan, S. Structure, function, and evolution of 
plant O-methyltransferases. Genome 2007, 50, 1001-1013. 
204. Singh, S.; Phillips, G. N., Jr; Thorson, J. S. The structural biology of enzymes involved in natural 
product glycosylation. Nat. Prod. Reports 2012, 29, 1201–1237. 
205. Chang, A.; Singh, S.; Phillips, G. N., Jr.; Thorson, J. S. Glycosyltransferase structural biology 
and its role in the design of catalysts for glycosylation. Curr.Opinion Biotech. 2012, 22, 800–808. 
206. Nothaft, H.; Szymanski, C. M. Protein glycosylation in bacteria: sweeter than ever. Nat. Rev. 
Microbiol. 2010, 8, 765–778. 
207. Calo, D.; Kaminski, L.; Eichler, J. Protein glycosylation in Archaea: sweet and extreme. 
Glycobiology 2010, 20, 1065–1076. 
208. Choi, W. S.; Wu, X.; Choeng, Y. H.; Mahmud, T.; Jeong, B. C.; Lee, S. H.; Chang, Y. K.; Kim, 
C. J.; Hong, S. K Genetic organization of the putative biosynthetic gene cluster including the 2-
epi-5-epi valiolone synthase gene in Streptomyces albus ATCC 21838. Appl. Microbiol. 
Biotechnol. 2008, 80, 637−645.  
209. McCasland, G. E.; Furuta, S.; Durham, L. J. Alicyclic carbohydrates. XXIX. Synthesis of 
pseudohexose (2,3,4,5-tetrahydroxycyclohexanemethanol).  J. Org. Chem. 1966, 31, 1516-1521. 
210. Suami, T.; Ogawa, S.; Takata, M.; Yasuda, K.; Suga, A.; Takei, K.; Uematsu, Y. Synthesis and 
sweet tasting pseudo--fructopyranose. Chem. Lett. 1985, 719-722 
211. Suami, T.; Ogawa, S.; Takata, M.; Yasuda, K.; Takei, K.; Suga, A. Pseudo-sugars. XIV. 
Synthesis of sweet-tasting pseudo--DL-fructopyranose. Bull. Chem. Soc. Jpn. 1986, 59, 819-
821. 
212. Ogawa, S.; Uematsu, Y.; Yoshida, S.; Sasaki, N.; Suami, T.J. Pseudo sugars. Part XVIII. 
Synthesis and sweetness of pseudo--D- and L-fructopyranose. J. Carbohydr. Chem. 1987, 6, 
471-478. 
213. Berg, J. M.; Tymoczko, J. L.; Stryer, L. Biochemistry. 5th edition. Freeman, 2002. Chapter 8. 
Section 8.5. 
214. Etxeberria, U.; de la Garza, A. L.; Canapión, J.; Martínez, J. A.; Milagro, F. I. Antidiabetic 
effects of natural plant extracts via inhibition of carbohydrate hydrolysis enzymes with emphasis 
on pancreatic alpha amylase. Expert Opin. Ther. Targets 2012, 16, 1-29. 
215. Parry, R. J.; Burns, M. R.; Skae, P. N.; Hoyt, J. C.; Pal, B.  Carbocyclic analogs of  D-ribose-5-
phosphate: synthesis and behavior with 5-phosphoribosyl α-1-pyrophosphate synthetases Bioorg. 
Med. Chem. 1996, 4, 1077-1088. 
 46
                                                                                                                                               
216. Kim, J. H.; Wolle, D.; Haridas, K.; Parry, R. J.; Smith, J. L.; Zalkin, H. A stable carbocyclic 
analog of 5-phosphoribosyl-1-pyrophosphate to probe the mechanism of catalysis and regulation 
of glutamine phosphoribosylpyrophosphate amidotransferase. J. Biol. Chem. 1995, 270, 17394-
17399. 
217. Parry, R. J.; Haridas, K., Synthesis of 1α-pyrophosphoryl-2α,3α-dihydroxy-4β-
cyclopentanemethanol 5-phosphate, a carbocyclic analog of 5-phosphoribosyl-1-pyrophosphate 
(PRPP). Tetrahedron Lett. 1993, 34, 7013-7016. 
218. Duley, J. A.; Christodoulou, J.; de Brouwer, A.  P. M., The PRPP Synthetase Spectrum: What 
Does it Demonstrate About Nucleotide Syndromes?. Nucleosides, Nucleotides & Nucleic Acids 
2011, 30, 1129-1139. 
219. Tatibana, M.; Kita, K.; Taira, M.; Ishijima, S. Sonoda, T.; Ishizuka, T.; Iizasa, T.; Ahmad, I. 
Mammalian phosphoribosyl-pyrophosphate synthetase Adv. Enz. Regulation 1995, 35, 29-249. 
220. Fujimori, S. in Genetic bases of gout and hyperuricemia. I. PRPP synthetase superactivity. 
Genetic Errors Associated with Purine and Pyrimidine Metabolism in Humans: Diagnosis and 
Treatment.  Moriwaki, Y.; Yamamoto, T. eds. Research Signpost, Trivandrum, India, 2006, p. 6-
14. 
221. United States Food and Drug Administration. Guidance for Industry. Drug Interaction Studies-
Study Design, Data Analysis, and Implications for Dosing and Labeling. September 2006. 
Clinical Pharmacology. 
222. Fujimori, S. in Genetic bases of gout and hyperuricemia. I. PRPP synthetase superactivity. 
Genetic Errors Associated with Purine and Pyrimidine Metabolism in Humans: Diagnosis and 
Treatment.  Moriwaki, Y.; Yamamoto, T. eds. Research Signpost, Trivandrum, India, 2006, p. 6-
14. 
223. Becker, M. A.; Smith, P. R.; Taylor, W.; Mustafi. R.; Switzer, R. L, The genetic and functional 
basis of purine nucleotide feedback-resistant phosphoribosylpyrophosphate synthetase 
superactivity. J. Clin. Invest. 1995, 96, 2133–2141. 
224. Mazurek, S.; Boschek, C. B.; Eigenbrodt, E. The role of phosphometabolites in cell proliferation, 
energy metabolism, and tumor therapy. J. Bioenerg. and Biomemb. 1997, 29, 315-330. 
225. Sunamura, M.; Oonuma, M.; Motoi, F.; Abe, H.; Saitoh, Y.; Hoshida, T.; Ottomo S.; Horii, A.; 
Matsuno, S. Gene therapy for pancreatic cancer targeting the genomic alterations of tumor 
suppressor genes using replication-selective oncolytic adenovirus. Human Cell, 2002, 15, 138-
150. 
226. Ketudat Cairns, J. R.; Esen, A. β-Glucosidases. Cell Mol. Life Sci. 2010, 67, 3389–3405. 
227. Tatsuta, K. Total synthesis and chemical design of useful glycosidase inhibitors. Carbohydrate 
Mimics. Chapleur, Y. ed, Wiley, 1998, p. 283-305. 
228. Kallemeijn, W. W.; Aerts, J. M. F. G.; Witte, M. D.; Waennekes, T. Mechanism-based inhibitors 
of glycosidases: design and applications. Adv. Carbohydr. Chem. Biochem. 2014, 71, 297-308. 
229. Atsumi, S.; Iinuma, H.; Nosaka, C.; Umezawa, K. Biological activities of cyclophellitol. J. 
Antibiot. 1990, 43, 1579-1585. 
230. Pengthaisong, S.; Chen, C.-F.; Withers, S. G.; Kuaprasert, B.; Ketudat C. J. R. Rice. BGlu1 
glycosynthase and wild type transglycosylation activities distinguished by cyclophellitol 
inhibition. Carbohydr. Res. 2012, 352, 51-59. 
231. Gloster, T. M.; Madsen, R.; Davies, G. J. Structural basis for cyclophellitol inhibition of a β-
glucosidase. Org. Biomol. Chem. 2007, 5, 444-446. 
232. Nakata, M.; Chong, C.; Niwata, Y.; Toshima, K.; Tatsuta, K. A family of cyclophellitol analogs: 
synthesis and evaluation. J. Antibiot. 1993, 46, 1919-1922. 
233. Tai, V. W.-F.; Fung, P.-H.; Wong, Y.-S.; Shing, T. K. M. Synthesis and glycosidase-inhibitory 
activity of cyclophellitol analogs. Tetrahedron: Asymm. 1994, 5, 1353-1362. 
234. Tai, V. W.-F.; Fung, P.-H.; Wong, Y.-S.; Shing, T. K. M. Kinetic studies on cyclophellitol 
analogs-mechanism-based inactivators. Biochem. Biophys. Res. Comm. 1995, 213, 175-180. 
235. Li, K.-Y-; Jiang, J.; Witte, M. D.; Kallemeijn, W. W.; Donker-Koopman, W. E.; Boot, R. G.; 
Aerts, J. M. F. G.; Codee, J. D. C.; van der Marel, G. A.; Overkleeft, H. S. Exploring functional 
cyclophellitol analogues as human retaining beta-glucosidase inhibitors. Org. Biomol. Chem. 
2014, 12, 7786-7791. 
236. Tatsuta, K.; Niwata, Y.; Umezawa, K.; Toshima, K.; Nakata, M. Enantiospecific synthesis and 
biological evaluation of 1,6-epi-cyclophellitol. J. Antibiot. 1991, 44, 456-458. 
237. Atsumi, S.; Nosaka, Ch.; Ochi, Y.; Iinuma, H.; Umezawa, K.  Inhibition of experimental 
metastasis by an α-glucosidase inhibitor, 1,6-epi-cyclophellitol. Cancer Res. 1993, 53, 4896-
4899.  
 47
                                                                                                                                               
238. See for instance: (a) Kallemeijn, W. W.; Li, K.-Y.; Witte, M. D.; Marques, A. R. A.; Aten, J.; 
Scheij, S.; Jiang, J.; Willems, L. I.; Voorn-Brouwer, T. M.; van Roomen, C. P. A. A.; Ottenhoff, 
R.; Boot, R. G.; van den Elst, H.; Walvoort, M. T. C.; Florea, B. I.; Codee, J. D. C.; van der 
Marel, G. A.; Aerts, J. M. F. G.; Overkleeft, H. S. Novel Activity-Based Probes for Broad-
Spectrum Profiling of Retaining β-Exoglucosidases In Situ and In Vivo. Angew. Chem. Int. Ed. 
2012, 51, 12529-12533. 
239. Li, K.-Y.; Jiang, Ji.; Witte, M. D.; Kallemeijn, W. W.; van den Elst, H.; Wong, Ch.-S.; Chander, 
S. D.; Hoogendoorn, S.; Beenakker, T. J. M.; Codee, J. D. C.; Aerts, J. M. F. G.; van der Marel, 
G. A.; Overkleeft, H. S. Synthesis of Cyclophellitol, Cyclophellitol Aziridine, and Their Tagged 
Derivatives. Eur. J. Org. Chem. 2014, 6030-6043. 
240. Willems, L. I.; Beenakker, T. J. M.; Murray, B.; Gagestein, B.; van den Elst, H.; van Rijssel, E. 
R.; Codee, J. D. C.; Kallemeijn, W. W.; Aerts, J. M. F. G.; van der Marel, G A.; Overkleeft, H. 
S. Synthesis of α- and β-Galactopyranose-Configured Isomers of Cyclophellitol and 
Cyclophellitol Aziridine. Eur. J. Org. Chem. 2014, 6044-6056. 
241. Jiang, J.; Beenakker, T. J. M.; Kallemeijn, W. W.; van der Marel, G. A.; van den Elst, H.; Codee, 
J. D. C.; Aerts, J. M. F. G.; Overkleeft, H. S. Comparing Cyclophellitol N-Alkyl and N-Acyl 
Cyclophellitol Aziridines as Activity-Based Glycosidase Probes. Chem. Eur. J. 2015, 21, 10861-
10869. 
242. Nobuji, Y.; Noriko, C.; Takashi, M.; Shigern, U.; Kenzou, H.; Michiaki, I. Jpn. Kokai Tokkyo 
Koho JP06306000, 1994. 
243. Miller, T. W.; Arison, B. H.; Albers-Schonberg, G. Isolation of a cyclitol antibiotic: 2,3,4,5-
tetrahydroxycyclohexanemethanol. Biotechnol. Bioeng. 1973, 15, 1075-1080. 
244. Suami, T.; Ogawa, S. Chemistry of carba-sugars (pseudo-sugars) and their derivatives. Adv. 
Carbohydr. Chem. Biochem. 1990, 48, 21-90. 
245. Kamata, K.; Mitsuya, M.; Nishimura, T.; Eiki, J.; Nagata Y. Structural Basis for allosteric 
Regulation of the monomeric allosteric enzyme human Glucokinase. Structure 2004, 12, 429-
438. 
246. Postic, C.; Shiota, M.; Magnuson, M. A. Cell-specific roles of glucokinase in glucose 
homeostasis. Recent Progress in Hormone Research 2001, 56, 195-218. 
247. Miwa, I.; Hara, H.; Okuda, J.; Suami, T.; Ogawa, S. Inhibition of glucose-stimulated insulin 
release by pseudo-alpha-DL-glucose as a glucokinase inhibitor. Biochem. Int. 1985, 11, 809-816. 
248. Kitaoka, M.; Ogawa, S.; Taniguchi, H. A cellobiose phosphorylase from Cellvibrio gilvus 
recognizes only the beta-D-form of 5a-carba-glucopyranose. Carbohydr. Res. 1993, 247, 355-
359. 
249. Sugimoto, Y.; Suzuki, H.; Yamaki, H.; Nishimura, T.; Tanaka, N. Mechanism of action of 2-
crotonyloxymethyl-4,5,6-trihydroxycyclohex-2-enone, a sulfhydryl inhibitory antitumor 
antibiotic, and its effect on drug-resistant neoplastic cells. J. Antibiot. 1982, 35, 1222-1230. 
250.  Huntley, C. F. M.; Hamilton, D. S.; Creighton, D. J.; Ganem, B. Reaction of COTC with 
Glutathione: Structure of the Putative Glyoxalase I Inhibitor. Org. Lett. 2000, 2, 3143-3144. 
251. Kamiya, D.; Uchihata, Y.; Ichikawa, E.; Kato, K.; Umezawa, K. Reversal of anticancer drug 
resistance by COTC based on intracellular glutathione and glyoxalase I. Biorg. Med. Chem. Lett. 
2005, 15, 111-1114. 
252. Collu, F.; Bonsignore, L.; Casu, M.; Floris, C.; Gertsch, J.; Cottiglia, F. New cytotoxic saturated 
and unsaturated cyclohexanones from Anthemis maritima. Bioorg. Med. Chem. Lett. 2008, 18, 
1559-1562. 
253. Joseph, E.; Eiseman, J. L.; Hamilton, D. S.; Wang, H.; Tak, H.; Ding, Z.; Ganem, B.; Creighton, 
D. J. Molecular Basis of the Antitumos Activities of  2-Croyonyloxymethyl-2-cycloalkenones.  J. 
Med. Chem. 2003, 46, 194-196. 
254. Thornlley, P. J. Glyoxalase I-structure, function and a critical role in the enzymatic defence 
against glycation. Biochem. Soc. Trans. 2003, 31, 1343–1348. 
255. Creighton, D. J.; Hamilton, D. S. Brief history of glyoxalase I and what we have learned about 
metal ion-dependent, enzyme-catalyzed isomerizations. Arch. Biochem. Biophys, 2001, 387, 1–
10. 
256. Mirza, S.; Molleyres, L. P.; Vasella, A. Synthesis of a glyoxalase I inhibitor from Streptomyces 
griseosporeus Niida et Ogasawara. Helv. Chim. Acta 1985, 68, 986-996. 
257. Takayama, H.; Hayashi, K.; Koizumi, T. Enantioselective total synthesis of glyoxalase I inhibitor 
using asymmetric Diels-Alder reaction of a new chiral dienophile, (S)S-3-(3-
trifluoromethylpyrid-2-ylsulfinyl)acrylate. Tetrahedron Lett. 1986, 27, 5509-5512. 
 48
                                                                                                                                               
258. Shing, T. K. M.; Tang, Y. Enantiospecific synthesis of 2-crotonyloxy-(4R,5R,6R)-4,5,6-
trihydroxycyclohex-2-enone (COTC) from quinic acid. J. Chem. Soc. Chem. Comm. 1990, 312. 
259. Huntley, C. F. M.; Wood, H. B.; Ganem, B. A new synthesis of the glyoxalase-I inhibitor COTC. 
Tetrahedron Lett. 2000, 41, 2031-2034. 
260. Arthurs, C. L.; Wind, N. S.; Whitehead, R. C.; Stratford, I. J. Analogues of 2-crotonyloxymethyl-
(4R,5R,6R)-4,5,6-trihydroxycyclohex-2-enone (COTC) with anti-tumor properties. Bioorg. Med. 
Chem. Lett. 2007, 17, 553-557. 
261. Arthurs, C. L.; Raftery, J.; Whitby, H. L.; Whitehead, R.C.; Wind, N. S.; Stratford, I. J. Arene 
cis-dihydrodiols: Useful precursors for the preparation of analogs of the antitumor agent, 2-
crotonyloxymethyl-(4R,5R,6R)-4,5,6-trihydroxycyclohex-2-enone (COTC). Bioorg. Med. Chem. 
Lett. 2007, 17, 5974-5977. 
262. Arthurs, C. L.; Morris, G. A.; Piacenti, M.; Pritchard, R. G.; Stratford, I. J.; Tatic, T.; Whitehead, 
R. C.; Williams, K. F.; Wind, N. S. The synthesis of 2-oxyalkyl-cyclohex-2-enones, related to 
the bioactive natural products COTC and antheminone A, which possess antitumor properties. 
Tetrahedron 2010, 66, 9049-9060. 
263. Shing, T. K. M.; Wu, H. T.; Kwok, H. F.; Lau, C. B. S. Synthesis of chiral hydroxylated enones 
as potential anti-tumor agents. Bioorg. Med. Chem. Lett. 2012, 22, 7562-7565. 
264. Arthurs, C. L.; Lingley, K. F.; Piacenti, M.; Stratford, I. J.; Tatic, T.; Whitehead, R. C.; Wind, N. 
S. (-)-Quinic acid: a versatile precursor for the synthesis of analogs of 2-crotonyloxymethyl-
(4R,5R,6R)-4,5,6-trihydroxycyclohex-2-enone (COTC) which possess antitumor properties. 
Tetrahedron Lett. 2008, 49, 2410-2413. 
265. See: Dowling, P. M., Aminoglycosides and aminocyclitols. Antimicrobial Therapy in Veterinary 
Medicine. 5th Edition. Giguere, S.; Prescott, J. F.; Dowling, P. M. eds.  Wiley, 2013, p. 233-255. 
See also: Kudo, F.; Eguchi, T. Aminoglycoside Antibiotics: New Insights into the Biosynthetic 
Machinery of Old Drugs. Chem. Record 2016, 16, 4-18. 
266. Lewwellyn, N. M.; Spencer, J. B. Biosynthesis of 2-deoxystreptamine-containing 
aminoglycoside antibiotics. Nat. Prod. Report.  2006, 23, 864-874. 
267. Nango, E.; Eguchi, T.; Kakinuma, K Active Site Mapping of 2-Deoxy-scyllo-inosose Synthase, 
the Key Starter Enzyme for the Biosynthesis of 2-Deoxystreptamine. Mechanism-Based 
Inhibition and Identification of Lysine-141 as the Entrapped Nucleophile. J. Org. Chem. 2004, 
69, 593-600. 
268. Dykes, D.; Waud, W. Murine L1210 and P388 leukemias. Tumor Models in Cancer Research. 
Teicher, B, ed. Humana Press, Inc., 2002, pp.23-40. 
269. Herbst, R. S. Review of epidermal growth factor. Int. J. Radiat. Oncol. Biol. 2004, 59, 21-26. 
270. See Chanpoux, J. J. DNA topoisomerases: structure, function, and mechanism. Annu. Rev. 
Biochem. 2001, 70, 369-413. 
271. Numata, A.; Iritani, M.; Yamada, T.; Minoura, K.; Matsumura, E.; Yamori, T.; Tsuruo, T. Novel 
antitumor metabolites produced by a fungal strain from a sea hare. Tetrahedron Lett. 1997, 38, 
8215-8218. 
272. Javitt, N. B. Hep G2 cells as a resource for metabolic studies: lipoprotein, cholesterol, and bile 
acids. FASEB J. 1990, 4, 161-168.  
273. Bach, G.; Breiding-Mack, S.; Grabley, S.; Hammann, P.; Huetter, K.; Thiericke, R.; Uhr, H.; 
Wink, J.; Zeeck, A. Secondary metabolites by chemical screening. 22. Gabosines, new carba-
sugars from Streptomyces. Liebigs Ann. Chem. 1993, 241-250. 
274. Tang, Y.-Q.; Maul, C.; Hofs, R.; Sattler, I.; Grabley, S.; Feng, X.-Z.; Zeeck, A.; Thiericke, R. 
Gabosines L, N and O: new carbasugars from Streptomyces with DNA-binding properties. Eur. J. 
Org. Chem. 2000, 149-153. 
275. Maier, A.; Maul, C.; Zerlin, M.; Grabley, S.; Thiericke, R. Biomolecular-chemical screening. A 
novel screening approach for the discovery of biologically active secondary metabolites. II. 
Application studies with pure metabolites. J. Antibiot. 1999, 52, 952-959. 
276. Tsushiya, T.; Mikami, N.; Umezawa, S.; Umezawa, H.; Naganawa, H. KD16-U1, a new 
metabolite of Streptomyces. Isolation and structural studies. J. Antibiot. 1974, 27, 579-586. 
277. Winchester, B. Role of α-D-mannosidases in the biosynthesis and catabolism of glycoproteins. 
Biochem. Soc. Trans. 1984, 12, 522–524. 
278. Vidyasagar, A.; Sureshan, K. M. Total Synthesis and Glycosidase Inhibition Studies of (-)-
Gabosine J and Its Derivatives. Eur. J. Org. Chem. 2014, 2349-2356. 
279. Smetanina, O. F.; Kalinovskii, A. I.; Khudyakov, Y. V.; Moiseenko, O. P.; Pivkin, M. V.; 
Menzorova, N. I.; Sibirtsev, Y. T.; Kuznetsova, T. A. Metabolites of the marine fungus 
Aspergillus varians KMM 4630. Chem. Nat. Compd. 2005, 41, 243-244. 
 49
                                                                                                                                               
280. Trisuwan, K.; Rukachaisirikul, V.; Sukpondma, Y.; Preedanon, S.; Phongpaichit, S.; 
Rungjindamai, N.; Sakayaroj, J. Epoxydons and a Pyrone from the Marine-Derived Fungus 
Nigrospora sp. PSU-F5. J. Nat. Prod. 2008, 71, 1323-1326. 
281. Qin, S.; Hussain, H.; Schulz, B.; Draeger, S.; Krohn, K. Two new metabolites, epoxydine A and 
B, from Phoma sp. Helv. Chim. Acta 2010, 93, 169-174. 
282. Kakeya, H.; Miyake, Y.; Shoji, M.; Kishida, S.; Hayashi, Y.; Kataoka, T.; Osada, H. Novel non-
peptide inhibitors targeting death receptor-Mediated apoptosis. Bioorg. Med. Chem. Lett. 2003, 
13, 3743-3746. 
283. Mitsui, T.; Miyake, Y.; Kakeya, H.; Hayashi, Y.; Osada, H.; Kataoka, T. RKTS-33, an 
epoxycyclohexenone derivative that specifically inhibits Fas ligand-dependent apoptosis in CTL-
mediated cytotoxicity. Biosci. Biotechnol. Biochem. 2005, 69, 1923-1928. 
284. Gilmore, T. D. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene 2006, 25, 
6680–6884. 
285. Brasier, A. R. The NF-kappaB regulatory network. Cardiovascular Toxicol. 2006, 6, 111–130. 
286. Saitoh, T.; Suzuki, E.; Takasugi, A.; Obata, R.; Ishikawa, Y.; Umewaza, K.; Nishiyama, S. 
Efficient synthesis of (±)-parasitenone, a novel inhibitor of NF-κB. Bioorg. Med. Chem. Lett. 
2009, 19, 5383-5386. 
287. Wang, Ch.-H.; Wu, H. T.; Cheng, H. M.; Yen, T.-J.; Lu, I.-H.; Chang, H. Ch.; Jao, S.-Ch.; 
Shing, T. K. M.; Li, W.-S. Inhibition of Glutathione S-Transferase M1 by New Gabosine 
Analogs Is Essential for Overcoming Cisplatin Resistance in Lung Cancer Cells. J. Med. Chem. 
2011, 54, 8574-8581. 
288. Giard, D. J.; Aaronson, S. A.; Todaro, G. J.; Arnstein, P.; Kersey, J. H.; Dosik, H.; Parks, W. P. 
In vitro cultivation of human tumors: Establishment of cell lines derived from a series of solid 
tumors. J. Nat. Cancer Institute 1973, 51, 1417–1423. 
289. Engel, L. S.; Taioli, E.; Pfeiffer, R.; Garcia-Closas, M.; Marcus, P. M.; Lan, Q.; Boffetta, P.; 
Vineis, P.; Autrup, H.; Bell, D. A.; Branch, R. A.; Brockmöller, J.; Daly, A. K.; Heckbert, S. R.; 
Kalina, I.; Kang, D.; Katoh, T.; Lafuente, A.; Lin, H. J.; Romkes, M.; Taylor, J. A.; Rothman, N. 
Pooled analysis and meta-analysis of glutathione S-transferase M1 and bladder cancer: a HuGE 
review. Am. J. Epidemiol. 2002, 156, 95–109. 
290. Ogawa, S.; Aoyama, H.; Sato, T. Synthesis of an ether-linked alkyl 5a-carba-beta-D-glucoside, a 
5a-carba-beta-D-galactoside, a 2-acetamido-2-deoxy-5a-carba-beta-D-glucoside, and an alkyl 
5a'-carba-beta-lactoside. Carbohydr. Res. 2002, 337, 1979-1992. 
291. Becker, J. C.; Houben, R.; Schrama, D.; Voigt, H.; Ugurel, S.; Reisfeld, R. A. Mouse models for 
melanoma: a personal perspective. Exp. Dermatol. 2009, 19, 157–164. 
292. David, L. N.; Michael, M. C. Lipids. Lehninger Principles of Biochemistry, 4th edition. W H 
Freeman, 2005, p. 357. 
293. Mocchetti, I. Exogenous gangliosides, neuronal plasticity and repair, and the neurotrophins. Cell 
Mol. Life Sci. 2005, 62, 2283–2294. 
294. Jeanneret, V.; Vogel, P.; Renaut, P.; Millet, J.; Theveniaux, J.; Barberousse, V. Carbaxylosides 
of 4-ethyl-2-oxo-2H-benzopyran-7-yl as non-hydrolyzable, orally active venous antithrombotic 
agents. Bioorg. Med. Chem. Lett. 1998, 8, 1687-1688. 
295. Lefoix, M.; Tatibonët, A.; Cottaz, S.; Driguez, H.; Rollin, P. Carba-glucotropaeolin: the first 
non-hydrolyzable glucosinolate analogue, to inhibit myrosinase. Tetrahedron Lett. 2002, 43, 
2889-2890. 
296. Halkier, B. A.; Gershenzon, J. Biology and Biochemistry of Glucosinolates. Ann.Rev.Plant Biol. 
2006, 57, 303–333. 
297.  Yuasa, H.; Palcic, M. M.; Hindsgaul, O. Synthesis of the carbocyclic analog of uridine 5′-(α-
D4)-galactopyranosyl diphosphate) (UDP-Gal) as an inhibitor of β (1→4)-galactosyltransferase. 
Can. J. Chem. 1995, 73, 2190-2195. 
298. Cai, S.; Stroud, M. R.; Hakomori, S.; Toyokuni, T. Synthesis of carbocyclic analogs of 
guanosine 5'-(β-L-fucopyranosyl diphosphate) (GDP-fucose) as potential inhibitors of 
fucosyltransferases. J. Org. Chem. 1992, 57, 6693-6696. 
299. Norris, A. J.; Whitelegge, J. P.; Strouse, M. J.; Faull, K. F.; Toyokuni, T. Inhibition kinetics of 
carba- and C-fucosyl analogues of GDP-fucose against fucosyltransferase V: implication for the 
reaction mechanism. Bioorg. Med. Chem. Lett. 2004, 14, 571-573. 
300. Diaz, L.; Delgado, A. Medicinal chemistry of aminocyclitols. Curr. Med. Chem. 2010, 17, 2393-
2418. 
301. Ogawa, S.; Kanto, M. Design and synthesis of 5a-Carbaglycopyranosylamine glycosidase 
inhibitors. Curr. Top. Med Chem. 2009, 9, 58-75. 
 50
                                                                                                                                               
302. Chen, X.; Fan, Y.; Zheng, Y.; Shen, Y. Properties and Production of Valienamine and Its Related 
Analogues. Chem Rev. 2003, 103, 1955-1977. 
303. Zhang, J.-F.; Zheng, Y.-G.; Shen, Y.-Ch.. Inhibitory effect of valienamine on the enzymatic 
activity of honeybee (Apis cerana Fabr.) α-glucosidase. Pest. Biochem. Physiol. 2007, 87, 73-77. 
304. Zheng, Y.-G.; Shentu, X.-P.; Shen, Y.-Ch. Inhibition of porcine small intestinal sucrase by 
valienamine. J. Enzym. Inhibit. Med. Chem. 2005, 20, 49-53. 
305. Xue, Y.-P.; Jin, L-Q.; Liu, Z.-Q.; Zhang, J.-F.; Zheng, Y.-G. Purification and characterization of 
β-glucosidase from Reticulitermes flaviceps and its inhibition by valienamine and validamine. 
African J. Biotech. 2008, 7, 4595-4601. 
306. Zheng, Y.; Shentu, X.; Shen, Y. Inhibition of porcine small intestinal sucrase by validamine. 
Chin. J. Chem. Eng. 2005, 13, 429-432. 
307. Ogawa, S.; Oya, M.; Toyokuni, T.; Chida, N.; Suami, T. Pseudo-sugars. VIII. Synthesis of DL-
1-Epivalidamine and Related Compounds. Bull. Chem. Soc. Jpn. 1983, 56, 1441-1445. 
308. Ogawa, S.; Suzuki, M.; Tonegawa, T. New Synthesis of Penta-N,O-acetyl-DL-validamine and 
Pseudo-2-amino-2-deoxy-α-DL-mannopyranose, and Their Uronate Analogs. Bull. Chem. Soc. 
Jpn. 1988, 61, 1824-1826. 
309. Kameda, Y.; Kawashima, K.; Takeuchi, M.; Ikeda, K.; Asano, N.; Matsui, K. Preparation and 
biological activity of manno- and galacto-validamines, new 5a-carba-glycosylamines as alpha-
glycosidase inhibitors. Carbohydr. Res. 1997, 300, 259-264. 
310. Kameda, Y.; Asano, N.; Yoshikawa, M.; Takeuchi, M.; Yamaguchi, K.; Matsui, K.; Horii, S.; 
Fukase, H. Valiolamine, a new alpha-glucosidase inhibiting aminocyclitol produced by 
Streptomyces hygroscopicus. J. Antibiot. 1984, 37, 1301-1307. 
311. Horii, S.; Fukase, H.; Matsuo, T.; Kameda, Y.; Asano, N.; Matsui, K. Synthesis and alpha-D-
glucosidase inhibitory activity of N-substituted valiolamine derivatives as potential oral 
antidiabetic agents. J. Med. Chem. 1986, 29, 1038-1046. 
312. Chen, X.; Zheng, Y.; Shen, Y. Voglibose Basen, AO-128, one of the most important α-
glucosidase inhibitors. Curr. Med. Chem. 2006, 13, 109-116. 
313. Dabhi, A. S.; Bhatt, N. R.; Shah, M. J. Voglibose: an alpha glucosidase inhibitor. J. Clin. 
Diagnost. Res. 2013, 3023-3027. 
314. Konya, H.; Katsuno, T.; Tsunoda, T.; Yano, Y.; Kamitani, M.; Miuchi, M.; Hamaguchi, T.; 
Miyagawa, J.-i.; Namba, M. Effects of combination therapy with mitiglinide and voglibose on 
postprandial plasma glucose in patients with type 2 diabetes mellitus. Diabetes, Metabolic 
Syndrome and Obesity: Targets and Therapy 2013, 6, 317-325. 
315. Campo, V. L.; Aragao-Leoneti, V.; Carvalho, I. Glycosidases and diabetes: metabolic changes, 
mode of action and therapeutic perspectives. Carbohydr. Chem. 2013, 39, 181-203. 
316. Derosa, G.; Maffoli, P. α-Glucosidase inhibitors and their use in clinical practice. Archiv. Med. 
Sci. 2012, 8, 899-906; (d) Bin, B.-H.; Seo, J.; Yang, S. Ha; Lee, E.; Choi, H.; Kim, K.-H.; Cho, 
Eun-Gyung; L., Tae R. Novel inhibitory effect of the antidiabetic drug voglibose on 
melanogenesis. Exp. Dermatol. 2013, 22, 541-546. 
317. Lockhoff, O. Glycolipids as Immunomodulators: Syntheses and Properties Angew. Chem., Int. 
Ed. Engl. 1991, 30, 1611-1620. 
318. Tsunoda, H.; Sasaki, S.-I.; Furuya, T.; Ogawa, S. Pseudosugars, 36. Synthesis of Methyl 5a′-
Carbamaltoses Linked by Imino, Ether and Sulfide Bridges and Unsaturated Derivatives Thereof 
Liebigs Ann. Chem. 1996, 159-165. 
319. Ramstadius, C.; Hekmat, O.; Eriksson, L.; Stalbrand, H.; Cumpstey, I. β-Mannosidase and β-
hexosaminidase inhibitors: synthesis of 1,2-bis-epi-valienamine and 1-epi-2-acetamido-2-deoxy-
valienamine from D-mannose. Tetrahedron: Asym. 2009, 20, 795-807. 
320.  Scaffidi, A.; Stubbs, K. A.; Dennis, R. J.; Taylor, E. J.; Davies, G. J.; Vocadlo, D. J.; Stick, R. 
V. A 1-acetamido derivative of 6-epi-valienamine: an inhibitor of a diverse group of β-N-
acetylglucosaminidases. Org. Biomol. Chem. 2007, 5, 3013–3019. 
321. Frohwein, Y. Z.,; Gatt, S. Isolation of β-N-acetylhexosaminidase, β-N-acetylglucosaminidase, 
and β-N-acetylgalactosaminidase from calf brain. Biochem. 1967, 6, 2775–2782. 
322. Li, S. C.; Li, Y. T. Studies on the glycosidases of jack bean meal. 3. Crystallization and 
properties of β-N-acetylhexosaminidase. J. Biol. Chem. 1970, 245, 5153–5160. 
323. Liu, T.; Chen, L.; Ma, Q.; Shen, X.; Yang, Q. Structural insights into chitinolytic enzymes and 
inhibition mechanisms of selective inhibitors. Curr. Pharm. Design. 2014, 20, 754-770. 
324.  Tsunoda, H.; Ogawa, S. Pseudosugars, 33. Synthesis of some 5a-carbaglycosylamides, 
glycolipid analogs of biological interests. Liebigs Ann. Chem. 1994, 103-107. 
 51
                                                                                                                                               
325. Tsunoda, H.; Inokuchi, J.-I.; Yamagishi, K.; Ogawa, S. Pseudosugars, 35. Synthesis of 
glycosylceramide analogs composed of imino-linked unsaturated 5a-carbaglycosyl residues: 
Potent and specific gluco- and galactocerebrosidase inhibitors. Liebigs Ann. Chem. 1995, 279-
284. 
326. Ogawa, S.; Ashiura, M.; Uchida, C.; Watanabe, S.; Yamazaki, C.; Yamagishi, K.; Inokuchi, J.-I. 
Synthesis of potent β-D-glucocerebrosidase inhibitors: N-alkyl-β-valienamines. Bioorg. Med. 
Chem. Lett. 1996, 6, 929-932. 
327. Ogawa, S.; Mito, T.; Taiji, E.; Jimbo, M.; Yamagishi, K.; Inokuchi, J. Synthesis and biological 
evaluation of four stereoisomers of PDMP-analogue, N-(2-decylamino-3-hydroxy-3-phenylprop-
1-yl)-β-valienamine, and related compounds. Bioorg. Med. Chem. Lett. 1997, 7, 1915-1920. 
328. Ogawa, S.; Kobayashi, Y.; Kabayama, K.; Jimbo, M.; Inokuchi, J.-I. Chemical modification of 
beta-glucocerebrosidase inhibitor N-octyl-beta-valienamine: synthesis and biological evaluation 
of N-alkanoyl and N-alkyl derivatives. Bioorg. Med. Chem. 1998, 6, 1955-1962. 
329. Horii, S.; Fukase, H.; Matsuo, T.; Kameda, Y.; Asano, N.; Matsui, K. Synthesis and α-D-
glucosidase inhibitory activity of N-substituted valiolamine derivatives as potential oral 
antidiabetic agents. J. Med. Chem. 1986, 29, 1038-46. 
330. Kameda, Y.; Asano, N.; Yoshikawa, M.; Matsui, K.; Horii, S.; Fukase, H. J. N-Substituted 
valienamines, alpha-glucosidase inhibitors. J. Antibiot. 1982, 35, 1624–1626.  
331. Lysek, R.; Schuetz, C.; Favre, S.; O'Sullivan, A.C.; Pillonel, Ch.; Kruelle, T.; Jung, P. M. J.; 
Clotet-Codina, I.; Este, J. A.; Vogel, P. Search for α-glucosidase inhibitors: New N-substituted 
valienamine and conduramine F-1 derivatives. Bioorg. Med. Chem., 2006, 14, 6255-6282. 
332. Kapferer, P.; Birault, V.; Poisson, J.; Vasella, A. Synthesis and evaluation as glycosidase 
inhibitors of carbasugar-derived spirodiaziridines, spirodiazirines, and spiroaziridines. Helv. 
Chim. Acta 2003, 86, 2210-2227. 
333. Wang, Y.; Bennet, A.J. A potent bicyclic inhibitor of a family 27 α-galactosidase. Org. Biomol. 
Chem. 2007, 50, 1731-1738. 
334. Suzuki, Y.; Ogawa, S.; Sakakibara, Y. Chaperone therapy for neuronopathic lysosomal diseases: 
competitive inhibitors as chemical chaperones for enhancement of mutant enzyme activities. 
Persp. Med. Chem. 2009, 3, 7-19. 
335. Suzuki, Y. Chemical chaperone therapy for GM1-gangliosidosis. Cell. Mol. Life Sci. 2008, 65, 
351-353. 
336. Suzuki, Y. β-Galactosidase deficiency: an approach to chaperone therapy. J. Inherited Metabolic 
Dis. 2006, 29, 471-476. 
337. Ogawa, S.; Kanto, M.; Suzuki, Y. Development and medical application of unsaturated 
carbaglycosylamine glycosidase inhibitors. Mini-Rev. Med. Chem. 2007, 7, 679-691. 
338. Matsuda, J.; Suzuki, O.; Oshima, A.; Yamamoto, Y.; Noguchi, A.; Takimoto, K.; Itoh, M.; 
Matsuzaki, Y.; Yasuda, Y.; Ogawa, S.; Sakata, Y.; Nanba, E.; Higaki, K.; Ogawa, Y.; Tominaga, 
L.; Ohno, K.; Iwasaki, H.; Watanabe, H.; Brady, R. O.; Suzuki, Y. Chemical chaperone therapy 
for brain pathology in GM1-gangliosidosis. Proc. Natl. Acad. Sci. U. S. A. 2003, 100, 15912-
15917. 
339. Lin, H.; Sugimoto, Y.; Ohsaki, Y.; Ninomiya, H.; Oka, A.; Taniguchi, M.; Ida, H.; Eto, Y.; 
Ogawa, S.; Matsuzaki, Y.; Sawa, M.; Inoue, T.; Higaki, K.; Nanba, E.; Ohno, K.; Suzuki, Y. N-
octyl-beta-valienamine up-regulates activity of F213I mutant beta-glucosidase in cultured cells: a 
potential chemical chaperone therapy for Gaucher disease. Biochim. Biophys. Acta 2004, 1689, 
219-228. 
340. Hossain, M. A.; Higaki, K.; Saito, S.; Ohno, K.; Sakuraba, H.; Nanba, E.; Suzuki, Y.; Ozono, K.; 
Sakai, N. Chaperone therapy for Krabbe disease: potential for late-onset GALC mutations. J. 
Human Gen. 2015, 60, 539-545. 
341. Kuno, S.; Higaki, K.; Takahashi, A.; Nanba, E.; Ogawa, S. Potent chemical chaperone 
compounds for GM1-gangliosidosis: N-substituted (+)-conduramine F-4 derivatives. Med. Chem. 
Med. 2015, 6, 306-310. 
342. Suzuki, Y.; Ichinomiya, S.; Kurosawa, M.; Matsuda, J.; Ogawa, S.; Iida, M.; Kubo, T.; Tabe, M.; 
Itoh, M.; Higaki, K.; Nanba, E.; Ohno, K. Therapeutic chaperone effect of N-Octyl 4-Epi-β-
valienamine on murine GM1-gangliosidosis. Mol. Gen. Metabol. 2012, 106, 92-98. 
343. Kuno, S.i; Takahashi, A.; Ogawa, S. Transformation of quercitols into 4-methylenecyclohex-5-
ene-1,2,3-triol derivatives, precursors for the chemical chaperones N-octyl-4-epi-β-valienamine 
(NOEV) and N-octyl-β-valienamine (NOV). Bioorg. Med. Chem. Lett. 2011, 21, 7189-7192. 
 52
                                                                                                                                               
344. Luan, Z.; Li, L.; Ninomiya, H.i; Ohno, K.; Ogawa, S.; Kubo, T.; Iida, M.; Suzuki, Y. The 
pharmacological chaperone effect of N-octyl-β-valienamine on human mutant acid β-
glucosidases. Blood Cell. Mol. Dis. 2010, 44, 48-54. 
345. Suzuki, Y.; Ichinomiya, S.; Kurosawa, M.; Ohkubo, M.; Watanabe, H.; Iwasaki, H.; Matsuda, J.; 
Noguchi, Y.; Takimoto, K.; Itoh, M.; Tabe, M.; Iida, M.; Kubo, T.; Ogawa, S.; Nanba, E.; Higaki, 
K.; Ohno, K.; Brady, R. O. Chaperone therapy for neuronopathic lysosomal diseases: 
competitive inhibitors as chemical chaperones for enhancement of mutant enzyme activities. Ann. 
Neurol. 2007, 62, 671-675. 
346. Lei, K; Ninomiya, H.; Suzuki, M.; Inoue, T.; Sawa, M.; Iida, M.; Ida, H.; Eto, Y.; Ogawa, S.; 
Ohno, K.; Suzuki, Y. Enzyme enhancement activity of N-octyl-β-valienamine on β-glucosidase 
mutants associated with Gaucher disease. Biochim. Biophys. Acta 2007, 1772, 587-596. 
347. Hossain M. A.; Shinpo M.; Ozono K.i; Higaki K.Nanba E.; Suzuki Y.Sakai N. Chemical 
chaperone treatment for galactosialidosis: Effect of NOEV on β-galactosidase activities in 
fibroblasts. Brain Develop. 2016, 38, 175-80. 
348. Suzuki H.; Ohto U.; Higaki K.; Nanba E.; Mena-Barragan T.; Aguilar-Moncayo M.; Ortiz Mellet 
C.; Garcia Fernandez, J. M; Suzuki Y.; Shimizu T. Structural basis of pharmacological 
chaperoning for human β-galactosidase. J. Biol. Chem. 2014, 289, 14560-14568. 
349. Takamura A.; Higaki K.; Ninomiya, H.; Takai, T.; Matsuda J.; Iida M.; Ohno, K; Suzuki, Y.; 
Nanba, E. Lysosomal accumulation of Trk protein in brain of GM1-gangliosidosis mouse and its 
restoration by chemical chaperone. J. Neurochem. 2011, 118, 399-406. 
350. Luan, Z.; Ninomiya, H.; Ohno, K.; Ogawa, S.; Kubo, T.; Iida, M.; Suzuki, Y. The effect of N-
octyl-β-valienamine on β-glucosidase activity in tissues of normal mice. Brain Develop. 2010, 
32, 805-809. 
351. Parenti, G.; Andria, G.; Valenzano, K. J. Pharmacological Chaperone Therapy: Preclinical 
Development, Clinical Translation, and Prospects for the Treatment of Lysosomal Storage 
Disorders. Mol. Ther. 2015, 23, 1138-1148. 
352. Parenti, G.; Moracci, M.; Fecarotta, S.; Andria, G. Pharmacological chaperone therapy for 
lysosomal storage diseases. Future Med. Chem. 2014, 1031-1045. 
353. Winchester, B.; Vellodi, A.; Young, E. The molecular basis of lysosomal storage diseases and 
their treatment. Biochem. Soc. Trans. 2000, 28, 150–154. 
354. Ogawa, S.; Sekura, R.; Maruyama, A.; Yuasa, H.; Hashimoto, H. Synthesis and Glycosidase 
Inhibitory Activity of 5a-Carba-α-DL-fucopyranosylamine and-galactopyranosylamine. Eur. J. 
Org. Chem. 2000, 2089-2093. 
355. Ogawa, S.; Maruyama, A.; Odagiri, T.; Yuasa, H.; Hashimoto, H. Synthesis and Biological 
Evaluation of α-L-Fucosidase Inhibitors: 5a-Carba-α-L-fucopyranosylamine and Related 
Compounds. Eur. J. Org. Chem. 2001, 967-974. 
356. Ogawa, S.; Watanabe, M.; Maruyama, A.; Hisamatsu, S. Synthesis of an alpha-fucosidase 
inhibitor, 5a-carba-beta-L-fucopyranosylamine, and fucose-type alpha- and beta-DL-valienamine 
unsaturated derivatives. Bioorg. Med. Chem. Lett. 2002, 12, 749-752. 
357. Bernacki, R. J.; Niedbala, M. J.; Korytnyk, W. Glycosidases in cancer and invasion. Cancer 
Metastasis Rev. 1985, 4, 81-101. 
358. Ogawa, S.; Mori, M.; Takeuchi, G.; Doi, F.; Watanabe, M.; Sakata, Y. Convenient synthesis and 
evaluation of enzyme inhibitory activity of several N-alkyl-, N-phenylalkyl, and cyclic isourea 
derivatives of 5a-carba-alpha-DL-fucopyranosylamine. Bioorg. Med. Chem. Lett. 2002, 12, 
2811-2814. 
359. Ogawa, S.; Fujieda, S.; Sakata, Y.; Ishizaki, M.; Hisamatsu, S.; Okazaki, K. Synthesis and 
glycosidase inhibitory activity of some N-substituted 6-deoxy-5a-carba-beta-DL- and L-
galactopyranosylamines. Bioorg. Med. Chem. Lett. 2003, 13, 3461-3463. 
360. Williams, G. J.; Thorson, J. S. Natural product glycosyltransferases: properties and applications. 
Adv. Enzymol. Related Areas Mol. Biol. 2009, 76, 55–119. 
361. Kajihara, Y.; Hashimoto, H.; Ogawa, S. Galactosyl transfer ability of β-(1→ 4)-
galactosyltransferase toward 5a-carba-sugars. Carbohydr. Res. 2000, 323, 44-48. 
362. Qian, H.; Hu, B.; Wang, Z.; Xu, X.; Hong, T. Effects of validamycin on some enzymatic 
activities in soil. Environ. Monit. Asses. 2007, 125, 1-8. 
363.  Ishikawa, R.; Shirouzu, K.; Nakashita, H.; Teraoka, T.; Arie, T. Control efficacy of validamycin 
A against Fusarium wilt correlated with the severity of phytotoxic necrosis formed on tomato 
tissues. J. Pest. Sci. 2007, 32, 83-88. 
 53
                                                                                                                                               
364. Naik, B. M.; John, P.; Solanky, K. U.; Mahatma, L.; Mehta, B. P.; Sabalpara, A. N. Evaluation 
of newer fungicides for the management of foliar pathogens of banana. Pestology 2010, 34, 40-
43. 
365. Lee, Y. H.; Choi, Ch. W.; Kim, S. H.; Yun, J. G.; Chang, S. W.; Kim, Y. S.; Hong, J. K. 
Chemical pesticides and plant essential oils for disease control of tomato bacterial wilt. Plant 
Pathol. J. 2012, 28, 32-39. 
366. Guirao-Abad, J. P.; Sanchez-Fresneda, R.; Valentin, E.; Martinez-Esparza, M.; Arguelles, J. C. 
Analysis of validamycin as a potential antifungal compound against Candida albicans. Int. J.  
Microbiol. 2013, 16, 217-225. 
367. Nwaka, S.; Holzer H. Molecular biology of trehalose and the trehalases in the yeast 
Saccharomyces cerevisiae. Prog Nucleic Acid Res Mol Biol. 1998, 58, 197-237. 
368. Barraza, A.; Sánchez, F. Trehalases: A neglected carbon metabolism regulator?. Plant Sign. 
Behav, 2013. Published online: www.landesbioscience.com/journals/psb/article/24778. 
369. Mueller, J.; Boller, T.; Wiemken, A. Trehalose and trehalase in plants: recent developments. 
Plant Sci. 1995, 112, 1-9. 
370. Tatun, N.; Wangsantitham, O.; Tungjitwitayakul, J.; Sakurai, S. Trehalase activity in fungus-
growing termite, Odontotermes feae (Isoptera: Termitideae) and inhibitory effect of validamycin. 
J. Econ. Entomol. 2014, 107, 1224-1232. 
371.  Lenka, S.; Bhaktavatsalam, G.; Medhi, B. Fungicidal control of sheath blight of rice. J. Plant 
Prot. Environ. 2010, 7, 53-55. 
372. Bhuvaneswari, V.; Raju, S. K. Efficacy of new fungicide of strobilurin group against rice sheath 
blight caused by Rhizoctonia solani. J. Mycol. Plant Physiol. 2013, 43, 447-451. 
373.  Wakae, O.; Matsuura, K. Characteristics of validamycin as a fungicide for Rhizoctonia disease 
control. Review Plant Protect. Res. 1975, 8, 81-92. 
374. Serneels, J.; Tournu, H.; Van Dijck, P. Tight control of trehalose content is required for efficient 
heat-induced cell elongation in Candida albicans. J. Biol. Chem. 2012, 287, 6873-36882. 
375. Wang, Z.-J.; Ji, S.; Si, Y.-X.; Yang, J.-M.; Qian, G.-Y.; Lee, J.; Yin, S.-J. The effect of 
validamycin A on tyrosinase: Inhibition kinetics and computational simulation. Int. J. Biol. 
Macromol. 2013, 55, 15-23. 
376. Lee, Y. H.; Cho, Y.-S.; Lee, S. W.; Hong, J. K. Chemical and biological controls of balloon 
flower stem rots caused by Rhizoctonia solani and Sclerotinia sclerotiorum. Plant Pathol. J. 
2012, 28, 156-163. 
377. Berg, H.; Tam, N. T. Use of pesticides and attitude to pest management strategies among rice 
and rice-fish farmers in the Mekong Delta, Vietnam. Int. J.Pest Manag. 2012, 58, 153-164. 
378. Li, H.; Su, H.; Kim, S. B.; Chang, Y. K.; Hong, S.-K.; Seo, Y.-G.; Kim, C.-J. Enhanced 
production of trehalose in Escherichia coli by homologous expression of otsBA in the presence 
of the trehalase inhibitor, validamycin A, at high osmolarity. J. Biosci. Bioeng. 2012, 113, 224-
232. 
379. Qian, K.; Shi, T.; Tang, T.; Zhang, S.; Liu, X.; Cao, Y. Preparation and characterization of nano-
sized calcium carbonate as controlled release pesticide carrier for validamycin against 
Rhizoctonia solani. Microchim. Acta 2011, 173, 51-57. 
380. Best, M.; Koenig, K.; McDonald, K.; Schueller, M.; Rogers, A.; Ferrieri, R. A. Inhibition of 
trehalose breakdown increases new carbon partitioning into cellulosic biomass in Nicotiana 
tabacum. Carbohyd. Res. 2011, 346, 595-601. 
381.  Biswas, A.; Bag, M. K. Strobilurins in management of sheath blight disease of rice: a review. 
Pestology 2010, 34, 23-25. 
382. Jin, L.-Q.; Zheng, Y.-G. Inhibitory effects of validamycin compounds on the termites trehalase. 
Pest. Biochem. Physiol. 2009, 95, 28-32. 
383. Lopez, M; Tejera, N. l A.; Lluch, C. Validamycin A improves the response of Medicago 
truncatula plants to salt stress by inducing trehalose accumulation in the root nodules. J. Plant 
Physiol. 2009, 166, 1218-1222. 
384. Gibson, R. P; Gloster, T. M.; Roberts, S.; Warren, R A. J; Storch de Gracia, I.; Garcia, A.; 
Chiara, J. L; Davies, G. J. Molecular basis for trehalase inhibition revealed by the structure of 
trehalase in complex with potent inhibitors. Angew. Chem. Int. Ed. 2007, 46, 4115-4119. 
385. Madigan, M.; Martinko J. ed. Brock Biology of Microorganisms (11th ed.). Prentice Hall, 2005. 
386. Nioh, T.; Mizushima, S. Effect of validamycin on the growth and morphology of Pellicularia 
sasakii. J. Gen. Appl. Microbiol. 1974, 20, 373-383. 
387. Uyeda, M.; Ikeda, A.; Machimoto, T.; Shibata, M. Effect of Validamycin on Production of Some 
Enzymes in Rhizoctonia solani. Agric. Biol. Chem. 1985, 49, 3485-3491. 
 54
                                                                                                                                               
388.  Kido, Y.; Nagasato, T.; Ono, K.; Fujimoto, Y.; Uyeda, M.; Shibata, M. Change in a Cell-Wall 
Component of Rhizoctonia solani Inhibited by Validamycin. Agric. Biol. Chem. 1986, 50, 1519-
1525. 
389. Uyeda, M.; Ikeda, A.; Ogata, T.; Shibata, M. Effect of Validamycin on β-D-Glucan-degrading 
Enzymes from Rhizoctonia solani. Agric. Biol. Chem. 1986, 50, 1885-1886. 
390. Kameda, Y.; Asano, N.; Yamaguchi, T.; Matsui, K. Validoxylamines as trehalase inhibitors J. 
Antibiot. 1987, 40, 563-565. 
391. Asano, N.; Takeuci, M.; Kameda, Y.; Matsui, K.; Kono, Y. Trehalase inhibitors, validoxylamine 
A and related compounds as insecticides. J. Antibiot. 1990, 43, 722-726. 
392. Shigemoto, R.; Okuno, T.; Matsuura, K. Effects of validamycin A on the growth of and trehalose 
content in mycelia of Rhizoctonia solani incubated in a medium containing several sugars as the 
sole carbohydrate. Ann. Phytopath. Soc. Jpn. 1992, 58, 685-690. 
393. Asano, N.; Yamaguchi, T.; Kameda, Y.; Matsui, K. Effect of validamycins on glycohydrolases 
of Rhizoctonia solani. J. Antibiot. 1987, 40, 526-532. 
394. Ogawa, S.; Sato, K.; Miyamoto, Y. Synthesis and trehalase-inhibitory activity of an imino-linked 
dicarba-α,α-trehalose and analogues thereof. J. Chem. Soc., Perkin Trans. 1 1993, 691-696. 
395. Ogawa, S.; Nishi, K.; Shibata, Y. Synthesis of a carba-sugar analog of trehalosamine, [(1S)-
(1,2,4/3,5)-2-amino-3,4-dihydroxy-5-hydroxymethyl-1-cyclohexyl] alpha-D-glucopyranoside, 
and a revised synthesis of its beta anomer. Carbohydr. Res. 1990, 206, 352-360. 
396. Ogawa, S.; Shibata, Y. Synthesis of biologically active pseudo-trehalosamine: [(1S)-(1,2,4/3,5)-
2,3,4-trihydroxy-5-hydroxymethyl-1-cyclohexyl] 2-amino-2-deoxy-alpha-D-glucopyranoside. 
Carbohydr. Res. 1988, 176, 309-315. 
397. Fukuhara, K.-i.; Murai, H.; Murao, S. Isolation and strusture-activity relationship of some 
amylostatins (F-1b fraction) produced by Streptomuces diastaticus subsp. Amylostaticus No. 
9410.  Agric. Biol. Chem. 1982, 46, 1941-1945. 
398. Namiki, S.; Kangouri, K.; Nagate, T.; Hara, H.; Sugita, K.; Noda, K.; Tarumoto, Y.; Amura, S. 
Studies on the. α.-glucoside hydrolase inhibitor, adiposin. IV. Effect of adiposin on intestinal 
digestion of carbohydrates in experimental animals. J. Antibiot. 1982, 35, 1167-1173. 
399. Kangouri, K.; Namiki, S.; Nagate, T.; Hara, H.; Sugita, K.; Omura, S. Studies on the. α-
glucoside hydrolase inhibitor, adiposin. III. α-Glucoside hydrolase inhibitory activity and 
antibacterial activity in vitro. J. Antibiot. 1982, 35, 1160-1166. 
400. Itoh, J.; Omoto, S.; Shomura, T.; Ogino, H.; Iwamatsu, K.; Inouye, S.; Hidaka, H. Oligostatins, 
new antibiotics with amylase inhibitory activity. I. Production, isolation and characterization. J. 
Antibiot. 1981, 34, 1424-1428. 
401. Shibata, Y.; Kosuge, Y.; Ogawa, S. Synthesis and biological activities of methyl 
oligobiosaminide and some deoxy isomers thereof. Carbohydr. Res. 1990, 199, 37-54. 
402. Ogawa, S.; Shibata, Y.; Kosuge, Y.; Yasuda, K.; Mizukoshi, T.; Uchida, C. Synthesis of potent 
α-glucosidase inhibitors: methyl acarviosin analogue composed of 1,6-anhydro-β-D-
glucopyranose residue. J. Chem. Soc., Chem. Commun. 1990, 1387-1388. 
403. Shibata, Y.; Kosuge, Y.; Mizukoshi, T.; Ogawa, S. Chemical modification of the sugar part of 
methyl acarviosin: synthesis and inhibitory activities of nine analogues. Carbohydr. Res. 1992, 
228, 377-398. 
404. Ogawa, S.; Aso, D. Chemical modification of the sugar moiety of methyl acarviosin: synthesis 
and inhibitory activity of eight analogues containing a 1, 6-anhydro bridge. Carbohydr. Res. 
1993, 250, 177-184. 
405. Ogawa, S. Chemical synthesis of glycosylamide and cerebroside analogs composed of carba 
sugars. Methods Enzymol. 1994, 247, 136-143. 
406. Ogawa, S.; Sasaki, S.-i.; Tsunoda, H. Synthesis of carbocyclic analogues of the mannosyl 
trisaccharide: ether- and imino-linked methyl 3,6-bis(5a-carba-alpha-D-mannopyranosyl)-3,6-
dideoxy-alpha-D-mannopyran osides. Carbohydr. Res. 1995, 274, 183-196. 
407. Ogawa, S.; Furuya, T.; Tsunoda, H.; Hindsgaul, O.; Stangier, K.; Palcic, M. M. Synthesis of 
beta-D-GlcpNAc-(1->2)-5a-carba-alpha-D-Man p-(1->6)-beta-D-Glcp-O(CH2)7CH3: a reactive 
acceptor analog for N-acetylglucosaminyltransferase-V. Carbohydr. Res. 1995, 271, 197-205. 
408. Hakomori, S. I. Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. 
Adv. Cancer Res. 1989, 52, 257-331; (b) Schachter, H. In Molecular Glycobiology; Fukuda, M., 
Hindsgaul, O., Eds.; IRL Press: Oxford, New York, Tokyo, 1994; pp 86-162. 
409. Prieels, J. P.; Monnom, D.; Dolmans, M.; Beyer, T. A.; Hill, R. L. Co-purification of the Lewis 
blood group N-acetylglucosaminide alpha 1 goes to 4 fucosyltransferase and an N-
 55
                                                                                                                                               
acetylglucosaminide alpha 1 goes to 3 fucosyltransferase from human milk. J. Biol. Chem. 1981, 
256, 10456-10463. 
410. Macher, B. A.; Holmes, E. H.; Swiedler, S. J.; Stults, C. L. M.; Srnka, C. A. Human α-1–3 
fucosyltransferases. Glycobiology 1991, 1, 577-584; (c) de Vries, T.; Knegtel, R. M. A.; Holmes, 
E. H.; Macher, B. A. Fucosyltransferases: structure/function studies. Glycobiology 2001, 11, 
119R-128R 
411. Becker, D. J.; Lowe, J. B. Fucose: biosynthesis and biological function in mammals. 
Glycobiology 2003, 13, 41R-53R. 
412. Ogawa, S.; Matsunaga, N.; Palcic, M. M. Synthesis of biological interest: ether linked octyl 5a’-
carba--lactosaminide and related compounds Carbohydr. Lett. 1997, 2, 299-306. 
413. Ogawa, S.; Matsunaga, N.; Li, H.; Palcic, M. M. Synthesis of Ether- and Imino-Linked Octyl N-
Acetyl-5a′-carba-β-lactosaminides and -isolactosaminides: Acceptor Substrates for α-(1 3/4)-
Fucosyltransferase, and Enzymatic Synthesis of 5a′-Carbatrisaccharides. Eur. J. Org. Chem. 
1999, 631-642. 
414. Ogawa, S.; Gamou, K.; Kugimiya, Y.; Senba, Y.; Lu, A.; Palcic, M. M. Synthesis of  octyl-N-
acetyl-5a-carba-lactos-aminide ans –isolactosminide: acceptor substrates for 1,3-
fucosyltransferase V and 2,3-(N)-sialyltransferase. Carbohydr. Lett. 2000, 3, 451-456. 
415. Okazaki, K.; Nishigaki, S.; Ishizuka, F.; Kajihara, Y.; Ogawa, S. Potent and specific 
sialyltransferase inhibitors: imino-linked 5a'-carbadisaccharides. Org. Biomol. Chem. 2003, 1, 
2229-2230. 
416. Kawamura, N.; Kinoshita, N.; Sawa, R.; Takahashi, Y.; Sawa, T.; Naganawa, H.; Hamada, M.; 
Takeuchi, T. Pyralomicins, novel antibiotics from Microtetraspora spiralis. I. Taxonomy and 
production.  J. Antibiot. 1996, 49, 706−709. 
 
 
 
 
 
 
 
  
 
